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Abstract  
All viruses strategically alter the anti-viral immune response to their benefit. The 
goal of this thesis was to examine how the vaccinia virus (VACV) K1 protein, which is 
encoded by the K1L gene, modulates the immune response in vitro and in vivo. In vitro, 
the K1 protein has multiple immunomodulatory effects in tissue culture models of 
infection. We have previously published that the K1 protein inhibits double-stranded 
RNA-dependent protein kinase (PKR) activation. A consequence of this function is that 
K1 inhibits PKR-induced NF-kB activation during VACV infection. However, transient 
expression of K1 also inhibits Toll-like receptor (TLR)-induced NF-kB activation. This 
suggested that K1 had a second NF-kB inhibitory mechanism that is PKR-independent. 
This possibility was explored by expressing K1 independently of infection and 
stimulating NF-kB under conditions that minimized or excluded PKR activation. Using 
these approaches, I found a second NF-kB inhibitory function for K1: K1 inhibited 
nuclear acetylation of the RelA (p65) subunit of NF-kB. Moreover, p65-CBP interactions 
were blocked in the presence of K1.  However, K1 did not preclude NF-kB binding to 
oligonucleotides containing kB binding sites.  This implies that NF-kB-promoter 
interactions still occurred in the presence of K1, but NF-kB cannot properly trigger 
transcriptional activation because K1 antagonizes acetylation of RelA. These data show 
that K1 has multiple mechanisms to inhibit NF-kB activation and, in comparison to all 
known VACV NF-kB inhibitory proteins, K1 acts at one of the most downstream events 
of NF-kB activation. A second goal of my thesis was to understand the contribution of 
K1 in vivo. I determined that a K1L-less vaccinia virus (vDK1L) was less pathogenic than 
wild-type VACV in intranasal and intradermal models of infection. Decreased 
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pathogenicity correlated with diminished virus replication in intranasally-infected mice. 
However, in intradermally-inoculated ears, vDK1L replicated to nearly identical levels as 
VACV, implying that the decreased immune response to vDK1L infection, not virus 
replication, dictated lesion size. Several lines of evidence support this theory. First, 
vDK1L induced slightly less edema than vK1L as revealed by histopathology and non-
invasive quantitative ultrasound technology (QUS). Second, infiltrating immune cell 
populations were decreased in vDK1L-infected ears. Third, cytokine and chemokine gene 
expression was decreased in vDK1L-infected ears. While these results identified the 
biological basis for smaller lesions they remained puzzling: because K1 antagonizes NF-
kB in vitro, anti-viral gene expression was expected to be higher during vDK1L infection. 
Despite these diminished innate immune responses, vDK1L vaccination induced a 
protective VACV-specific CD8+ T cell response and protected against a lethal VACV 
challenge. Thus, vDK1L is a unique construct that limits pathogenesis, yet still elicits 
protective immunity. We propose that continued studies of vDK1L may uncover novel 
relationships between pathogenesis and immunity, information that has practical 
applications for vaccine design. 
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Chapter 1: Introduction  
 
1.1 Viruses, evolution, and human health 
Although excluded from the definition of life, viruses have and continue to 
influence the evolution of organisms from all domains of life. For example, viruses 
contributed to the development of the placenta; the mammalian syncytin gene is a 
retroviral env gene that was permanently recombined into the genome [71]. In addition, it 
is estimated that one-third of the adaptive mutations acquired by human proteins is a 
consequence of the arms race against viruses [27]. This demonstrates that viruses provide 
a constant pressure to their host. Despite this impact on diverse biological processes, 
viruses are mostly studied as causative agents of devastating diseases. One example is the 
variola virus (VARV), the causative agent of smallpox, which belongs to the Poxviridae 
family. Smallpox is the only human disease that has been declared eradicated. A myriad 
of viral diseases continue to be a threat to public health, and eradication of them by 
vaccination remains a grand challenge in human health. One key to combatting viruses is 
to understand how they evade the immune system. Our lab utilizes poxviruses as a model 
system to study virus-host interactions. Information gained from this system allows a 
better understanding of how viruses cause disease, which in turn aids in the development 
of vaccines and antivirals. The work in this thesis focuses on the modulation of the host 
immune system by the poxviral ankyrin repeat protein K1, which is encoded by vaccinia 
virus (VACV). 
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1.2 Poxviruses 
Overview  
The Poxviridae family consists of brick-shaped double-stranded DNA (dsDNA) 
viruses that infect a variety of hosts, from invertebrates to vertebrates [73]. Unique 
amongst DNA viruses, poxviruses replicate entirely in the cytoplasm of their host cell by 
encoding their own replication machinery. Although giant viruses such as Pandoravirus 
[81] and Pithovirus [2] have genomes of 2.5 megabase pairs (Mb) and 650 kilobase pairs 
(kb), respectively, poxviruses are still considered large viruses with genomes of 
approximately 200 kb and dumbbell shaped capsids of 360 x 270 x 250 nanometers (nm) 
[73]. 
 
Life cycle 
The poxvirus life cycle is characterized by a cascade of gene expression: early, 
intermediate and late (Figure 1.1). The life cycle begins with the attachment of the virion 
to the host cell, followed by either direct fusion of the viral envelope with the plasma 
membrane [5] or by macropinocytosis [68], which allows the core to enter the cell. 
Although studies report that binding of the virion involves association with integrin b1 
[50] and CD98 [91], a specific cell-host receptor that triggers fusion has not been yet 
identified [72]. Once the core is inside the cell, the class of early genes is transcribed and 
mRNA is synthesized within the core. The mRNAs are then translated into early proteins, 
including immune defense factors such as like the K1 protein (the focus of this thesis), 
enzymes needed for DNA replication, and transcription factors for intermediate gene 
transcription. Next, uncoating occurs, and the viral DNA is released and replicated in the 
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cytoplasm. The intermediate class of viral genes is then expressed and encodes for 
transcription factors that aid in the transcription of late genes [73]. Finally, the class of 
late genes is expressed which encodes early transcription factors and nonstructural 
proteins that will be encapsulated to form intracellular mature virions (IMVs). Some 
virions acquire a single Golgi or endoplasmic reticulum membrane and these are referred 
to as intracellular enveloped virions (IEVs) [74]). Then, they are transported by 
microtubules to the periphery where their membrane fuses with the plasma membrane 
resulting in exocytosis of extracellular enveloped virions (EEVs), which are efficient in 
cell-to-cell spread. In contrast, IMVs are released by cell lysis, are more stable and 
important for organism-to-organism transmission [73]. 
 
Poxviruses as human pathogens 
There are several medically-relevant poxviruses. The most notorious poxvirus is 
the VARV, the causative agent of smallpox, which killed 300-500 million people 
worldwide [54]. Although smallpox was declared eradicated by the World Health 
Organization in 1980, other poxviruses are still relevant to the medical community. The 
molluscum contagiosum virus (MCV) is a poxvirus that infects children as well as 
sexually active adults [23]. MCV causes benign lesions (molluscum contagiosum; MC) 
that self-resolve within months after initial infection [83]. However, these lesions can 
persist for longer time periods in immunocompromised individuals, and this infection 
often develops into giant molluscum [60]. Monkeypox virus (MPXV) is closely related to 
VARV. MPXV can also infect humans and it can be transmitted from monkeys or other 
animal reservoirs to humans. MPXV causes a smallpox-like disease and is endemic in 
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several African countries [63]. It also caused an outbreak in the USA in 2003, when 
MPXV-infected prairie dogs were shipped from Africa to the USA, and infected prairie 
dogs bit and transmitted MPXV to 53 people [62]. Since human-to-human transmission 
of MPXV is not efficient, the outbreak was contained. However, close attention must be 
paid to MPXV as a continued potential threat to public health.  The work of this thesis 
focuses on the VACV K1 protein. Interestingly, while MPXV expresses the K1 protein, 
neither VARV nor MCV does [22] [93]. This exemplifies that each poxvirus likely faces 
different immune system challenges, and as a result each poxvirus expresses its own 
arsenal of proteins to battle these challenges. Studying proteins such as K1 aids to 
understand the diverse challenges encountered by and countermeasures used by these 
closely-related viruses.  
 
1.3 Vaccinia virus modulation of host innate immune responses 
Vaccinia virus overview 
Work in this thesis project characterizes the VACV K1 protein. VACV is the 
best-studied poxvirus. It was the first virus to be observed under the microscope, to be 
grown in cell culture, to be appropriately tittered, and to be purified and chemically 
analyzed [73]. In addition, VACV was used as the vaccine during the smallpox 
eradication campaign [54]. Originally, it was thought that cowpox virus (CPXV) was 
used as the smallpox vaccine and that VACV originated from CPXV. However, more 
recent studies now show that VACV origins trace back to horsepox virus (HSXV) instead 
of CPXV [82].  
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Despite the eradication of smallpox, VACV continues to be medically important 
for several reasons. First, the current smallpox vaccine, which is still delivered to military 
personnel due to the potential use of smallpox as a bioweapon, is sub-optimal. The 
current vaccine has an unacceptably high rate of morbidity and mortality, and can cause 
severe adverse effects in immunocompromised individuals. Second, due to its success as 
a vaccine, VACV is studied as a potential vaccine vector to protect against infectious 
diseases such as AIDS and as an oncolytic therapy for several cancers [88]. Moreover, 
VACV is used as a model organism to study host-pathogen interactions [96]. 
Approximately 20% of a poxvirus genome is devoted to coding for immune 
evasion proteins. VACV is no exception as it encodes multiple inhibitors of the host 
immune response. Examples of extracellular defense proteins that it encodes include: 
inhibitors of complement, chemokine and cytokine binding proteins, as well as secreted 
inhibitors of Natural Killer (NK) cells. VACV also encodes for intracellular inhibitors 
that target: pathogen recognition receptors, Nuclear Factor kappa B (NF-kB), Interferon 
Regulated Factors (IRFs), apoptosis and antigen presentation [96]. Interestingly, VACV 
not only encodes inhibitors for multiple cellular immune pathways, but it also encodes 
multiple proteins that target the same pathway. For example, two main cellular anti-viral 
responses are Protein Kinase R (PKR) and NF-kB activation.  VACV encodes at least 3 
and 10 proteins, respectively, to inhibit PKR and NF-kB [96]. These are discussed below. 
As described the VACV K1 protein inhibits both signaling pathways. 
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PKR 
It is important to discuss PKR here because i) the K1 protein inhibits PKR 
activation [107, 108] and ii) PKR also activates NF-kB (Figure 1.2). The second chapter 
of this thesis uses multiple approaches to show that K1 inhibition of NF-kB is not due to 
K1 inhibition of PKR. Thus, to appreciate this work, one must understand PKR 
activation.  
PKR is a serine/threonine kinase activated by dsRNA, a byproduct of poxvirus 
infection, [32]. The dsDNA genome of a poxvirus encodes genes on both the top and 
bottom strands of DNA.  Transcripts of the top strand are described as going leftward to 
rightward, while transcription from the bottom strand is described as going rightward to 
leftward. During the transcription of poxvirus DNA, double-stranded RNAs (dsRNAs) 
are formed [20] when rightward and leftward transcripts overlap, and these dsRNAs 
could activate anti-viral cellular responses such as PKR [32].  PKR detects and binds to 
30 bp dsRNA, and then PKR undergoes homodimerization and autophosphorylation at 
residues T446 and T451.  Once activated, PKR phosphorylates eukaryotic translation 
initiator factor alpha 2 (eIF2a). As a result, host cell translation is halted as a mechanism 
to control viral replication [105]. It was originally thought that dsRNA was only formed 
during transcription of intermediate and late genes. However, work from our lab 
demonstrated that dsRNAs are also generated during transcription of early genes [107]. 
Interestingly, PKR was discovered due to the observation that IFN treatment of 
VACV-infected cells blocked virus mRNA translation. At the time it was known that 
dsRNAs are produced during VACV infection and prevent protein synthesis [31, 70]. It 
was hypothesized that a kinase was responsible for this response, which led to the search 
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and discovery of PKR [32]. This is an example of how the study of VACV allows the 
discovery of new aspects the of anti-viral immune response. 
 
NF-kB 
NF-kB is a transcription factor, initially identified as a nuclear protein bound to 
an enhancer element of the gene that encodes the kappa light chain of an immunoglobulin 
[92]. It is a master regulator of genes that control innate immune responses, apoptosis, 
inflammation, and oncogenesis [77]. NF-kB stimulates the inflammatory response by 
inducing pro-inflammatory gene expression and mediating the classical signs of 
inflammation: rubor, calor and dolor [9]. Five proteins belong to the NF-kB family: RelA 
(p65), NF-kB1 (p50), NF-kB2 (p52) c-Rel and RelB. These proteins form homodimers 
and heterodimers within the cell, and the best studied is the p65-p50 heterodimer. 
Inactive NF-kB is in the cytoplasm of every unstimulated cell because it is associated 
with one of its inhibitory factors: IkBα, IkBβ or IkBε [46].   The IkB proteins possess 
ankyrin repeat domains (ARDs), domains known for protein-protein interactions, and 
which mediate NF-kB-IkB interactions [49].  These interactions mask the nuclear 
localization signal of NF-kB, which keeps NF-kB in the cytoplasm during resting state 
[44]. 
In chapter 2 I evaluate how the K1 protein inhibits NF-kB activation. Here I 
describe the NF-kB signal transduction pathway, which can be stimulated by a variety of 
ligand-receptor interactions such as pathogen recognition receptor (e.g. LPS-Toll-like 
receptor (TLR) 4) and cytokine-receptor interactions such as TNF-TNFR [43]. 
Regardless of the stimuli, all signaling converges at the I kappa kinase (IKK) complex 
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[47]. Upon stimulation, the IKK complex phosphorylates IkBa, which leads to its 
polyubiquitination by the b-TrCP E3 ubiquitin ligase and subsequent proteasomal 
degradation [89]. As a result of IkBa degradation, the nuclear localization signal of NF-
kB is exposed, and NF-kB translocates to the nucleus and activates the transcription of its 
target genes [44] (Figure 1.3). 
NF-kB is present in every cell type, and it controls the expression of hundreds of 
genes. Thus, NF-kB activation needs to be tightly regulated.  In addition to the regulation 
provided by members of the IkB family, post-translational modifications of NF-kB play a 
fundamental role in controlling the transcriptional activity.  Acetylation, phosphorylation, 
methylation, and ubiquitination are examples of RelA post-translational modifications.  
The effect of each post-translational modification on the transcriptional activity of NF-kB 
is dependent on (i) the modification, (ii) the RelA residue affected (iii) and the source of 
stimulus [48].  For example, acetylation of residue K310 on RelA enhances the 
transcriptional activity of NF-kB by recruiting coactivators such as CBP/p300 [36]. In 
contrast, acetylation of K122 and K123 on RelA reduces transcriptional activity of NF-
kB [52].  As discussed in chapter 2, I have found that the K1 protein prevents acetylation 
of RelA. 
 
Vaccinia virus modulation of NF-kB 
As with many viruses [56], poxviruses inhibit NF-kB activation [78]. The focus 
of this thesis was to determine how the K1 protein inhibits NF-kB activation. In addition 
to K1, VACV encodes at least nine other inhibitors of NF-kB: A46, A52, K7, B14, N1, 
C4, A49, M2, and E3 [11] [90] [18] [24] [26] [61] [34] [75] [94] (Figure 1.3). Each 
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protein uses a different mechanism to inhibit different NF-kB activation pathways. For 
example, A46 interacts with Toll-IL-1 receptor (TIR) domain-containing proteins to 
inhibit NF-kB from multiple inducers that trigger TLR-induced NF-kB activation [97]. 
A52 and K7 inhibit downstream of TLRs and IL-1 because they interact with IL-1 
receptor-associated kinase (IRAK) 2 and tumor necrosis factor receptor-associated factor 
(TRAF) 6 [11, 76]. In contrast, B14 and N1 target the IKK complex [18] [24]. C4 inhibits 
at or downstream of IKK, but before p65 translocation [26]. M2 prevents NF-kB 
activation via an ERK2 pathway [34].  A49 employs molecular mimicry to b-TrCP 
substrates and sequesters the E3 ligase b-TrCP responsible for cellular IkBa 
ubiquitination [61]. In addition, it has been reported that E3 inhibits the expression of IL-
6, TNF, IFN and inhibitin beta A (INHBA) via the NF-kB pathway [75]. Each of these 
poxviral inhibitors target NF-kB prior to nuclear translocation. In contrast, here I found 
that the K1 protein targets NF-kB in the nucleus. Recently, Summer et al. suggested that 
there is at least one more uncharacterized NF-kB inhibitor, demonstrating the complexity 
and importance of targeting this signaling pathway [99]. One would hypothesize that 
these protein inhibitors are redundant. However, as it will be discussed later in detail, 
deletion of any of these inhibitors results in a virus that is now attenuated in animal 
models of infection. I show here that this is also the case for the K1L gene: deletion of the 
K1L gene from a VACV results in a less virulent virus. This implies that each viral NF-
kB inhibitory protein has unique functions that may be important for different host cell 
types.  
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1.4 The K1 protein 
The K1 protein is encoded by the K1L gene. It is also referred as WR032 
according to new poxvirus nomenclature. In this thesis, the traditional terminology will 
be employed. Thus K1L will be used. It is expressed as an early and intermediate gene 
during a VACV infection, and is a 32.5 kDa product [38]. The K1L gene is conserved 
within members of the Orthopoxvirus genus except that K1L is not present in camelpox 
virus and VARV [22, 41]. For VARV, the K1L gene contains a premature stop codon. 
The K1 crystal structure was elucidated and revealed that it consists of nine 
ankyrin repeat domains (ARDs). While there are many other ARD-containing proteins 
expressed by poxviruses, K1 is unique amongst other orthologs because K1 lacks an F-
box motif, a domain that other ARDs use to bind to E3 ligase complexes to execute their 
functions. Additionally, while most cellular ARD-containing proteins interact with 
functional binding partners by their concave surface, critical residues for the host range 
function of K1 (discussed later) are located on the convex surface of its structure [57], 
solidifying K1 as a unique ARD-containing protein. 
 
K1's host range function  
There are a family of poxvirus genes that are classified as host range genes.  
These are defined as genes that are required for virus replication [79].  The K1L gene is 
one such host range gene. This function of K1L was discovered in 1981, when Drillien et 
al. reported a VACV mutant that, unlike wild-type VACV, is unable to replicate in most 
human cell lines [25]. This mutant virus has an 18 kb deletion. Later, Gillard et al. 
identified that the K1L gene is the minimal region to rescue the replication of this virus 
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[38]. Thus, K1L is a host range gene. The K1L host range is slightly different for human 
versus rabbit cell lines.  While the restriction is characterized by a shutdown of both early 
viral and cellular protein synthesis during infection in rabbit cell lines, this restriction 
occurs during intermediate protein synthesis in human cell lines.  [79]. In addition, in 
human cell lines, insertion of C7L can rescue virus replication of a VACV lacking the 
K1L gene (vDK1L), indicating that the K1 and C7 proteins have homologous host range 
function. However, in rabbit cell lines, insertion of the C7L gene can not rescue viral 
replication of vDK1L, thus the K1L gene is required for virus replication [80]. In this 
thesis, I evaluated the host range phenotype in murine cells of VACV lacking just the 
K1L gene or both K1L and C7L genes (DK1LDC7L) as both animal models of infection 
are in mice.  
There is great interest in understanding the host range mechanism for K1: solving 
this puzzle provides potential means to control virus replication and perhaps control 
poxvirus pathogenesis. In a cellular genome-wide siRNA screening, sterile alpha motif 
domain containing 9 (SAMD9) was found to have a role in preventing DK1LDC7L 
replication in human cells [95]. Liu and McFadden reported that SAMD9 is an anti-viral 
stress response element that aids in the formation of anti-viral granules [58]. While wild-
type myxoma virus (MYXM) or VACV blocks formation of SAMD9-mediated granules, 
MYXM lacking the M062R gene (DM062) or DK1LDC7L induce anti-viral granules 
during infection. Moreover, viral replication of DM062 and DK1LDC7L was rescued in 
SAMD9 knockdown cell lines and no anti-viral granules were formed. While M062 
antagonizes SAMD9 by direct interaction which results in sequestration and 
redistribution of SAMD9, the mechanism employed by K1 or C7 to antagonize SAMD9 
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and promote viral replication remains to be determined. It has been shown that both K1 
and C7 proteins interact with SAMD9 [95], however, the relevance of these interactions 
remains unclear. Interestingly, SAMD9 can be induced by interferon (IFN) and 
interferon-regulated factor 1 (IRF-1), and the K1 protein inhibits IFN and IRF-1 mediated 
genes [66]. One hypothesis is that K1 antagonistic function of SAMD9 is dependent on 
its INF or IRF-1 inhibitory function.  
Interestingly, DK1LDC7L is also replication-deficient in mouse cells [65]. 
However, SAMD9 is not expressed in mouse cells, suggesting that there are additional 
cellular factors involved in this host-range restriction. Indeed, the siRNA screening also 
revealed that WD repeat-containing protein 6 (WDR6) and the methyltransferase FTSJ1 
also have roles in restricting replication of DK1LDC7L [95].  
 
Binding partners of K1 
ARDs are motifs that allow protein-protein interactions.  Thus, one hypothesis is 
that K1 mediates its effects (e.g. host range function or NF-kB inhibition) by binding to 
viral or cellular partners. In addition to SAMD9 [95], K1 has been found to interact with 
VACV protein C10 [64]. K1 has also been found to co-immunoprecipitate with cellular 
GTPase ACAP2 [12]. However, K1’s host range function is independent of its 
interactions with ACAP2 as K1 mutants unable to bind to ACAP have no effect on 
VACV replication and vice versa [67]. The biological relevance of these K1-mediated 
interactions remains to be elucidated. I also show here that K1 binds to the RelA subunit 
of NF-kB. However, whether this interaction is relevant for host range or for NF-kB 
inhibition remains to be determined.  
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PKR inhibition by the K1 protein 
In our lab, it was discovered that the K1 protein inhibits PKR activation [107, 
108]. First, it was observed that in the presence of K1, VACV inhibited phosphorylation 
of both PKR and eIF2a [108]. In further studies, our lab also found that the K1 protein 
prevented early and intermediate dsRNA formation in RK13 and HeLa cells, respectively 
[107]. Thus during VACV infection K1 prevents the formation of dsRNA to prevent PKR 
activation. Originally it was hypothesized that PKR inhibition was K1’s host range 
function as K1 mutants that no longer support viral replication are also defective on 
inhibiting PKR activation. However, knockdown of PKR does not rescue viral replication 
of DK1LDC7L. Thus inhibition of PKR is not K1’s host range function [108]. 
The mechanism by which the K1 protein inhibits dsRNA formation remains 
unclear. One hypothesis is that the K1 protein acts as a facilitator of translation; as a 
consequence, when the K1 protein is absent, an abundant amount of mRNA is present. 
Several studies support this hypothesis: i) in RK13 or HeLa cells infected with DK1L, 
only early or intermediate gene transcription occurs and ii) these early gene transcripts 
are detected for longer time periods in DK1L-infected cells compared to wild-type 
VACV. This accumulation of mRNAs could trigger the formation of dsRNA that could 
activate PKR [107]. Further studies are required to elucidate how the K1 protein could 
promote mRNA translation. 
 
Inhibition of NF-kB by the K1 protein 
In 2004, our lab published that K1 protein inhibits IkBa degradation during virus 
infection [94]. First, in RK13 and HeLa cells, Modified Vaccinia virus Ankara (MVA), 
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which lacks K1L, induces NF-kB driven luciferase transcription and IkBa degradation, 
while MVA/K1L does not. Also, RK13 DK1L-infected cells show IkBa degradation. 
Later studies identified that one mechanism for the K1 protein to inhibit NF-kB 
activation was by preventing PKR activation since mutants that no longer inhibit PKR are 
also unable to inhibit NF-kB [107]. In addition, NF-kB activation does not occur in 
PKRKD cells, indicating that during VACV infection, PKR is an activator of NF-kB 
[107]. PKR has been shown to activate NF-kB by interacting with the IKK complex 
[109], the kinase responsible for IkBa degradation. Thus the degradation of IkBa in 
DK1L infected cells is due to activation of the IKK complex by PKR (Figure 1.2). 
However, data from our lab and others [4] suggested that K1 possesses a PKR-
independent mechanism to inhibit NF-kB activation. Work in this thesis evaluated this 
hypothesis, which proved correct and data are shown in chapter 2. 
 
1.5 Vaccinia virus animal models of infection 
As mentioned earlier, VACV encodes multiple immune evasion proteins that 
target a myriad of cellular signaling pathways [96]. Studying these proteins and their 
molecular mechanisms of action is important for understanding viral pathogenesis and 
developing therapeutics. While cell culture systems are facile means to discover and 
study these viral immunomodulators, they cannot be used to understand how immune 
evasion molecules dictate severity of infection. There are several VACV animal models 
of infection that allow such questions to be answered.  The poxvirus field utilizes 
different routes of inoculation: intranasal, intradermal, intracranial, footpad, 
intraperitoneal, intravenous and subcutaneous. Each route has advantages and 
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disadvantages.  Here I will describe two of these inoculation routes, intradermal and 
intranasal, which were used to study the role of the K1 protein in vivo. They were chosen 
for several reasons. First, these are the two most widely used VACV animal models to 
study the contribution of VACV proteins to pathogenesis. Second, these models utilize 
the most natural routes of inoculation with ectromelia virus and VACV or during human 
vaccination. Third, the intranasal and intradermal routes mimic a systemic disease (like 
smallpox) and a dermal vaccination, respectively. This will allow us to better understand 
the pathogenesis of smallpox-like diseases as well as the immune response to vaccination 
with VACV, which is a potential vaccine vector for several diseases. 
 
Intranasal model 
Intranasal inoculation (IN) of mice with VACV results in an acute infection of the 
lower respiratory tract [86] [106]. Although this route of inoculation does not cause skin 
lesions like smallpox, IN infection with VACV mimics a smallpox infection in that it also 
causes a systemic disease. After an IN inoculation, the primary site of viral replication is 
the lungs. Since VACV western reserve (WR) strain is neurovirulent, VACV next 
spreads to the brain of infected mice [15]. Then, the virus disseminates to other organs 
such as the liver, kidney, spleens and ovaries [84]. The disease progression is monitored 
by assessing: i) weight changes, ii) clinical signs of illness such as conjunctivitis, fur 
ruffling, arched backs, difficulty breathing, moving and socializing and iii) virus titers of 
organs including lungs, brains, livers, spleens and ovaries  [106]. 
The immune response during IN infection is well-characterized. As early as 24 
hours post-infection, cytokines and chemokines such as IL-2, IL-6, TNFa, CXCL9, and 
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CXCL10 are expressed in the lungs [98]. By 48 hours post-infection, there is a significant 
increase in the number of cells in bronchoalveolar lavage fluids. These cells include 
macrophages, neutrophils, natural killer (NK) cells, and lymphocytes such as CD8+ and 
CD4+ T cells [84]. Macrophages and dendritic cells have been shown to drive the early 
innate response against VACV [10, 87]. Ultimately, CD8+ T cells protect against death 
via the secretion of IFN-g [39, 40]. This response is sufficient to protect mice in the 
absence of CD4+ T cells and B cells [39]. More recently, NK cells have been reported to 
be the primary producers of IFN-g in the lungs prior to the infiltration of CD8+ T cells 
and also contribute to protection against a respiratory infection with VACV [1].  
 
Intradermal model 
The intradermal model (ID) of infection was developed as an alternative to the IN 
route of infection [102]. This model is characterized by a highly localized infection, 
where lesions in the ears are formed and no signs of systemic illness are observed. As 
such, ID infection is a model that more closely represents smallpox vaccination or lesion 
formation that occurs during smallpox infection.  It consists of inoculating mice in the ear 
pinna with VACV. An ear lesion develops about 5-7 days post-infection and the lesion 
grows in size until 12 days post infection.  The lesion size decreases during the next 12-
14 days and scabbing forms.  
Mice are routinely inoculated with 102 or 104 PFU of virus. Interestingly, the 
amount of inoculum correlates with the lesion size: the lower the inoculum size, the 
smaller the lesion. Regardless, virus replication kinetics are similar for both doses, and 
the peak in virus titers in the ear is observed at day 5, regardless of the inoculum dose. 
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One explanation for this phenomenon could be that the number of host cells available for 
infection in the dermal layer of the ear is limited. Thus, a low dose of virus reaches this 
limit [101]. Regardless of the dose, viral titers peak at five days post-infection, plateau 
and then viral titers start to decrease approximately 11-12 days post-infection. 
The localized immune response to an ID infection with VACV virus is well-
known. This characterization was performed by examining the inflammatory response 
and infiltration of immune cells to the ear pinna longitudinally after infection.  There is 
minimal inflammation and cellular infiltration three days post-infection. Then, there is an 
influx of classical inflammatory monocytes (CD11c- Ly6cHI Ly6g-) and this population 
peaks at day five post infection [29]. Macrophages are also recruited by day 3 post-
infection. A variety of cytokines and chemokines are induced, with CXCL9 and CXCL10 
being the most predominant at day 5 post-infection [45]. Then, the development of 
lesions is observed as well as the entry of tissue-protective unconventional neutrophils 
(CD11b+ Lyg6+), which are attracted by unknown mechanisms. These cells outnumber 
the inflammatory monocytes by day seven and produce large amounts of Type I IFNs and 
reactive oxygen species (ROS). Depletion of these cells results in an increase in tissue 
damage, showing that these cells are tissue protective [29]. The number of lymphocytes 
gradually increases up to 17 days post infection, with peaks around days 9-11 post-
infection. The spread and replication of VACV in this model is controlled by phagocytes 
[29] [84] [51]. 
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Vaccinia virus virulence factors 
The use of the IN and ID models of infection has allowed the identification of 
dozens of VACV proteins that play a role in virus virulence [96]. Curiously, the deletion 
of some genes (e.g. B18R, C6L, F1L) [35, 100, 103] decreases the virulence of a virus 
compared to wild-type VACV, while the deletion of other genes (e.g. A41L, B15R, 169R) 
[3, 19, 98] increases the virulence of the virus during IN infection. Similar 
unpredictability occurs in the ID model of infection. To date, the field does not 
understand the reason for these different outcomes. In an attempt to understand this, 
studies have examined if there are differences in viral titer or cell recruitment to an area 
of infection when a gene of interest is present or absent from the virus. Below is a 
summary of virulence factors found during VACV intranasal and intradermal infections, 
focusing on those that inhibit the NF-kB signal transduction pathway (Table 1.1). 
 
Vaccinia virus NF-kB inhibitors as virulence factors during intranasal infection 
As mentioned earlier, VACV encodes at least ten intracellular inhibitors of NF-
kB and these inhibitors have non-redundant functions in vivo [96]. With the exception of 
K1 and M2, the effects of removing each of these proteins have been examined in vivo. 
Deletion of A46R, A49R, A52R, C4L, K7R, E3L or N1L results in a virus that has 
decreased virulence, as measured by decreased weight loss and signs of illness when 
using the IN route of infection. In contrast, deletion of B14R has no effect on virus 
virulence in this IN model of infection [61, 97] [42] [26] [8, 13] [6]. 
When examining viral replication in the primary site of infection (lungs), wild-
type VACV and mutant viruses DA49R, DC4L, and DK7R replicate to equal levels at 
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early times (2 days) post-infection. However, by day 5 post infection, the titers of 
mutants viruses are much lower than that of wild-type VACV [61] [26] [8]. In the case of 
DC4L infection, this decrease in virus replication correlates with an increase in the 
number of total immune cells in the bronchoalveolar fluids (BAL) at day 5 post-infection 
[26]. These data suggest that deletion of a VACV NF-kB inhibitor results in an increase 
in the number of immune cells to the site of infection, which may result in the decrease in 
viral titers at later time post-infection. 
Different results were observed when examining the lungs of DK7R-infected 
mice, which implies that each viral NF-kB inhibitory protein has unique physiological 
roles. During DK7R infection, there is no significant difference in the number of total 
immune cells infiltrating the lungs [8]. However, there is a higher proportion of cells 
expressing CD45, a leukocyte marker, as compared to cells observed in lungs from 
VACV-infected mice. The percentage of NK cells, CD8+ T cells, and CD4+ T cells is also 
higher during DK7R infection than wild-type VACV infection.  Although infection with 
DK7R results in less recruitment of neutrophils compared to wild-type VACV, there is an 
enhanced MHC class II expression by macrophages.  Moreover, NK cells and VACV 
specific CD8+ T cells from the lungs DK7R-infected mice have enhanced cytolytic 
properties as compared to those from VACV-infected mice.  
Although the VACV proteins discussed above inhibit NF-kB in cell culture, little 
is known about the link between their NF-kB inhibitory function and their contributions 
to VACV pathogenesis. Only one study has linked these two subject areas. The VACV 
N1 protein inhibits both apoptosis and NF-kB [24] [21].  Maluquer de Montes et al. 
created a panel of mutant N1 proteins that inhibited either apoptosis or NF-kB, and 
	   20 
reported that an infection with viruses expressing an N1 impaired from inhibiting NF-kB 
activation results in an attenuated infection, while a mutant N1 unable to inhibit apoptosis 
remains as virulent as wild-type VACV [59]. This shows that the NF-kB inhibitory 
function is critical for VACV pathogenesis. More studies are needed to understand the 
effects of removing a VACV NF-kB inhibitor regarding virulence. In this thesis project, I 
characterized the effects of removing one VACV inhibitor of NF-kB, K1, during an in 
vivo infection. Studying the effects of removing each of these proteins will shed light on 
why VACV encodes multiple inhibitors of the same signaling pathway. 
 
Vaccinia virus PKR inhibitors as virulence factors during intranasal infection 
Although the K1 protein inhibits NF-kB activation, it also inhibits PKR [107, 
108]. The VACV E3L and K3L genes also encode for proteins that inhibit PKR in tissue 
culture [7, 16]. A group of studies asked how each PKR inhibitory gene affects virus 
virulence.  It was interesting to observe that each virus had different properties with 
respect to virulence, suggesting that the E3 and K3 proteins are not redundant in vivo.  
For example, DE3L is attenuated in both intracranial and intranasal models of infection. 
This attenuation is partially resolved by deleting both PKR and RNAseL from the host, 
but very little when only PKR is absent [86].  In contrast, intranasal DK3L infection 
retains virulence because mice infected with DK3L have a similar weight loss as VACV 
infection. DK3L replicates in the lungs to levels similar to VACV, and this is likely one 
reason for the observed weight loss.  However, unlike VACV, DK3L infection does not 
spread to other organs. Interestingly, the K3L mediated viral dissemination was 
independent of PKR [86]. Thus, K3 and E3 likely target different host cell types or 
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modulate PKR activation at different times post-infection. K1 is the third VACV protein 
shown to inhibit PKR in vitro.  However, the role of K1 in virus virulence remains 
unknown, and this was the goal of chapter 3. 
 
Vaccinia virus NF-kB inhibitors as virulence factors during intradermal infection 
Several studies have examined the effects of removing a single VACV NF-kB 
antagonist on viral pathogenesis, using the ID inoculation route. IN and ID inoculations 
are not equivalent systems because some VACV mutants are attenuated in the IN model 
but not in the ID model. This is the case for the DC4L and DA49R viruses; while deletion 
of each of these genes results in fewer signs of illness in the intranasal infection, no 
differences are observed in lesions sizes compared to wild-type VACV [26, 61]. 
Conversely, there are some mutant VACV viruses that (DB14) in which the mutant virus 
is equally pathogenic as VACV via the IN route of inoculation, but induce smaller lesions 
during ID infection.  
When the number of immune cells was investigated, macrophages and T cells are 
higher in ears infected with ΔB14R at eight days post infection. Similar to what has been 
observed with other inhibitors of NF-kB in the IN model, there are no differences in viral 
titers at early time post infections. However, at day 11 post-infection, there is less viral 
replication of ΔB14R in the ears of infected mice. In addition, the number of total cells 
during ΔB14R infection is higher. The percentage of neutrophils is lower at eight days 
post-infection in ΔB14R infected ears, while the percentage of macrophages and 
lymphocytes were slightly higher [17]. 
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Several inhibitors of NF-kB contribute to VACV pathogenesis in both models of 
infection. For example, deletion of either K7L or N1L results in decreased clinical signs 
of illness during IN infection and smaller ear lesions during ID infection compared to 
wild-type VACV [8] [6].  
 
1.6 Vaccinia virus as a vaccine 
As mentioned previously, besides being an excellent model to study host-viral 
interactions, VACV is well known for its immunogenicity. The success of the smallpox 
eradication campaign is partly attributed to the use of VACV as a vaccine [28]. Although 
VACV is immunogenic, vaccination with VACV can result in several adverse effects 
such as generalized vaccinia, eczema vaccinatum, vaccinia keratitis, progressive vaccinia, 
and post-vaccinia encephalitis [55]. These side effects are more common in 
immunocompromised individuals. Despite smallpox eradication in 1980, smallpox is still 
a concern as it could be used as a bioweapon. Thus, military personnel are required to get 
a smallpox vaccination. The unacceptably high levels of morbidity and mortality in the 
armed forces who receive this vaccine is one reason to improve on the current smallpox 
vaccine.  
In addition to its use as the smallpox vaccine, VACV is being exploited as a 
potential vaccine vector to protect against other types of infectious diseases such as HIV 
and other viral, bacterial and parasitic infectious diseases. To this end, VACV is 
engineered to express antigenic genes from pathogens and the benefit to this approach is 
that heterologous gene products are expressed intracellularly, increasing the likelihood 
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that the heterologous protein will be expressed and presented by MHC I and MHC II 
molecules [88]. 
Finally, several labs use VACV as an oncolytic therapeutic. VACV is modified in 
a manner that infects and lyses tumor cells but not healthy cells.  This approach has been 
used to target several types of cancer including liver, skin and colorectal cancers [53]. 
 
Modifications to vaccinia virus to increase safety and immunogenicity 
As mentioned earlier, VACV vaccination has detrimental effects. Thus a safer, 
but equally immunogenic VACV is needed for vaccines and oncolytic viruses. Multiple 
labs have developed VACV that are attenuated, including MVA [37, 104]. These viruses 
lack multiple immune evasion genes that are otherwise present in wild-type VACV. 
Unfortunately, while these third-generation vaccines are safe, they are not appropriately 
immunogenic, and several boosters are required to get appropriate levels of protective 
immunization [30, 69]. Several labs have attempted to increase the immunogenicity of 
MVA by re-inserting genes from wild-type poxviruses into MVA to increase 
immunogenicity or deleting genes from wild-type poxviruses, such as VACV, to make 
them safer [33]. One example of removing a protein from VACV to increase its safety 
and immunogenicity is the deletion of N1, an inhibitor of NF-kB. Deletion of N1 resulted 
not only in an attenuated virus in both intranasal and intradermal models of infection, but 
also there was enhanced CD8+ T cell memory. These effects were dependent on N1’s 
NF-kB inhibitory function [85]. 
A constant debate in the poxvirus field is to determine what is the nature of 
VACV virus immunogenicity. Some attribute VACV immunogenicity to its modulation 
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of the immune system while others attribute it to its replication competency. Work in this 
thesis evaluated the effects of removing K1 in VACV immunogenicity while aiming to 
clarify which attribute of VACV is crucial for its success as a vaccine. 
 
1.7 Thesis outline  
The goal of this thesis project was to characterize the mechanism by which the K1 
protein inhibits NF-kB activation as well as to determine its contributions to VACV 
pathogenesis. I hypothesized that K1 possessed the ability to inhibit the NF-kB pathway 
directly and that it acts as a virulence factor. 
Chapter 2 describes a novel mechanism by which the K1 protein inhibits NF-kB 
activation [14]. Initially, it was believed that K1 inhibited NF-kB solely by inhibiting 
PKR activation [107], which is upstream of IkBa degradation [109]. However, I found 
evidence that indicates that the K1 protein has a PKR-independent mechanism where it 
allows IkBa degradation, RelA nuclear translocation, and RelA-DNA interactions [14]. 
However, acetylation of RelA at lysine 310 was inhibited by K1. In addition, RelA-CBP 
interactions were impaired in the presence of the K1 protein [14]. The identification of 
this novel mechanism was possible when the K1 protein was studied independently of 
viral infection. 
Although the K1 protein was discovered over 30 years ago, the contributions of 
K1 to VACV pathogenesis was not known. In Chapter 3 I characterized the effects of 
removing K1 on virulence utilizing the intranasal and intradermal models of infection. I 
found that the K1 protein is a virulence factor. I discovered that, while removing K1 had 
no effect on viral replication in vitro, mice showed fewer signs of illness compared to 
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wild-type VACV when introduced via the IN route. In addition, DK1L had decreased 
replication in the lungs and other visceral organs. In the ID model, mice infected with 
DK1L showed smaller ear lesions. DK1L showed similar titers but a decrease in the 
inflammatory response. Despite this, DK1L provided equal protection as wild-type 
VACV to a lethal challenge suggesting that VACV immunogenicity is due to its 
replication competency. 
Chapter 4 describes the efforts to elucidate the contributions of K1’s ARDs on 
NF-kB inhibition. This was the original scope of this thesis project. I have found that K1 
is not only structurally similar to IkBa, but it also co-immunoprecipitates with NF-kB. 
K1L mutants lacking one or two ARDs were cloned from viruses into a mammalian 
vector to study the contribution, if any, of each ARD. Although the mutants have yet to 
be tested, work on this chapter made available the tools to determine if NF-kB-K1 
interactions are relevant to NF-kB inhibition.  
Chapter 5 includes a summation of the findings in this thesis project as well as 
future directions that should be approached. While the initial goal of my project was to 
determine the relevance of K1’s ARDs on NF-kB inhibition, the outcome of my studies 
revealed a previously uncharacterized mechanism for NF-kB inhibition. In addition, these 
are the first studies that investigate K1 in vivo and revealed that a VACV lacking K1 has 
a unique phenotype compared to other mutant VACVs lacking NF-kB or PKR inhibitors. 
This shows that each of these proteins is crucial for VACV pathogenesis and re-
emphasizes the complexity of host-viral interactions. These findings open a new window 
for how VACV and other viruses modulate the host immune response and help to 
understand viral pathogenesis as well as to develop novel therapeutics. 
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1.8 Figures and Table 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 Poxvirus life cycle. Poxviruses bind and enter the host cell, then early 
mRNAs and proteins are made. Next, uncoating occurs followed by viral genome 
replication. Then transcription and translation of intermediate and late proteins occur 
followed by assembly and morphogenesis of intracellular mature virions (IMV). 
Intracellular enveloped virions (IEV) acquire an additional membrane and release of 
extracellular mature virions (EEV) occur, which can infect neighboring cells. 
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Figure 1.2 PKR mediated activation of NF-kB during vaccinia virus infection. 
Transcription of vaccinia virus’ mRNAs results in dsRNA formation. Monomeric protein 
kinase R (PKR) binds to dsRNAs, which triggers its dimerization and 
autophosphorylation. Once phosphorylated, PKR phosphorylates eukaryotic initiation 
factor 2 alpha (eIF2a), which results in a halt of protein translation. In addition, PKR can 
activate nuclear factor kappa b (NF-kB) via interactions with the I kappa kinase (IKK) 
complex. Activation of NF-kB results in the transcription of pro-inflammatory genes. 
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Figure 1.3 NF-kB signaling pathway is modulated by vaccinia virus proteins. Upon 
stimulation, the IKK complex phosphorylates IkBa, which leads to its polyubiquitination 
and subsequent proteasomal degradation. As a result of IkBa degradation, the nuclear 
localization signal of NF-kB (p65 and p50) is exposed, and NF-kB translocates to the 
nucleus. In the nucleus, NF-kB interacts with CBP/p300 and undergoes acetylation. 
Then, transcriptionally active NF-kB drives the transcription of immune response genes. 
Vaccinia virus encodes 10 inhibitors of NF-kB: A46, A49, A52, B14, C4, E3, K1, K7, 
M2, and N1. 
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Table 1.1 Effects of individually removing each of the ten VACV NF-kB inhibitors. 
  
NF-kB 
Inhibitor 
Intranasal 
Model (IN) 
Intradermal 
Model (ID) Effects of deleting NF-kB inhibitor 
A46 
(Also 
inhibits 
IRF3) 
Attenuated ND 
•   More total cells are recruited to the lungs at 
day 2 post-infection, while less total cells are 
found at days 5 and 8 post-infection. 
•   Increased immunogenicity. 
A49 Attenuated No phenotype 
•   No differences in viral titers at day 2 post 
infection. Decreased replication at days 5 and 
7 post-infection. 
A52 Attenuated ND ND 
B14 No phenotype Attenuated 
•   No differences in viral titers at day 2 post 
infection. Decreased replication at days 5, 7, 
and 11 post-infection. 
•   More total cells recruited at day 11 post-
infection. 
•   Decreased percentage of neutrophils at day 8 
post-infection, but macrophages and 
lymphocytes have slightly higher percentage. 
•   No differences in the absolute number of 
neutrophils, CD4+, CD8+, and γδ T cells, but 
increased number of macrophages and 
lymphocytes. 
C4 Attenuated No phenotype 
•   No differences in viral titers at day 2 post-
infection. Decreased replication at days 5 and 
8 post-infection. 
•   Significantly more cells in BALs at day 5 
post-infection. 
E3 
(Also 
inhibits 
PKR) 
Attenuated ND 
•   Less virus titers in all organs (nasal turbinates, 
lung, brain and spleen) at all time points 
tested (2, 4, 6 and 8 days post-infection). 
•   Both C- and N-terminus of E3 protein are 
required for pathogenesis. 
K1 Attenuated (Chapter 3) 
Attenuated 
(Chapter 3) 
IN:  
•   Less virus titers in all organs (lung, spleen, 
brain) and time points (2, 4, and 6 days post-
infection). 
ID:  
•   No differences in virus replication. 
•   Decreased edema and immune gene 
expression. 
•   Provides equal protection. 
K7 
(Also 
inhibits 
IRF-3) 
Attenuated Attenuated 
IN: 
•   No differences in viral titers at day 2 post- 
infection. Decreased replication at days 5 and 
7 post-infection. 
 
	   30 
Table 1.1 (cont.) 
 
 
ND: Not determined.  
 
 
 
 
 
 
 
 
 
   
 
•   No significant difference in overall number of 
cells. 
•   Decreased percentage of neutrophils at days 3 
and 6 post-infection. 
•   Increased number of total leukocytes at 4, 6, 
and 8 days post-infection. 
•   Higher percentage of MHC class II, T cells, 
NK cells, CD8+ cells. 
•   Lower percentage of CD4+ T cells. 
•   Enhanced cytotoxicity by NK cells and CD8+ 
T cells. 
M2 ND ND ND 
N1 (Also 
inhibits 
apoptosis) 
Attenuated 
 
Attenuated  
 
IN:  
•   No difference in viral titers at days 3. 
Decreased replication at days 6 and 11 post-
infection. 
•   Immunogenecity: Increased number of central 
and memory CD8+ T-cell populations in 
spleens. Increased CD8+ T cell cytotoxicity 
and lower virus titres after challenge. CD8+ 
memory T-cell function was increased with 
more IFN production.  
•   Attenuation and immunogenicity depends on 
N1’s NF-kB inhibitory function.  
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Chapter 2: Vaccinia virus K1 protein inhibits NF-kB activation by preventing RelA 
acetylation  
 
Originally published in the Journal of General Virology. Bravo Cruz A and Shisler J. 
97(10):2691-2702 doi:10.1099/jgv.0.000576. Published in partial fulfillment of the 
requirements for the degree of doctor of philosophy in Microbiology.   
 
2.1  Introduction 
Vaccinia virus (VACV) was used as a vaccine against variola virus (smallpox) 
infection [41]. Despite the elimination of smallpox in 1980, VACV remains important to 
the medical community. It is now being used as a vector for vaccines against other 
infectious diseases and as an oncolytic virus [24, 51]. In addition, VACV remains an 
excellent model for understanding immune responses to complex pathogens [55]. As such, 
the continued study of VACV identifies key virus-host interactions that can be exploited 
to the benefit of human health. 
The NF-kB transcription factor is critical for the host anti-viral defense because it 
activates genes involved in immunity and inflammation [2]. The RelA (p65) and NF-kB1 
(p50) heterodimer is the best-studied member of this family [2]. NF-kB is sequestered in 
the cytoplasm by IkBa [28]. Upstream proteins (e.g. TNF receptor-1) activate the IkB 
kinase (IKK) complex [25], and IKK phosphorylates IkBa [29]. As a consequence, IkBa 
is polyubiquitinated by the SCFbTrCP E3 ubiquitin ligase complex and degraded by the 
26S proteasome [28]. The freed NF-kB then migrates to the nucleus [26], where it 
undergoes several post-translational modifications that are required for its transcriptional 
activity, such as acetylation of RelA [30]. Originally, it was thought that RelA must be 
acetylated by CBP/p300 prior to NF-kB binding to its promoter. However, recent 
publications demonstrate that, for some genes, RelA migrates to a promoter already 
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bound by CBP/p300 [42].  In these cases, RelA is acetylated after it binds to the DNA-
CBP/p300 complex [42]. Regardless, once the promoter is occupied by NF-kB, 
transcription is initiated when the adjacent transcriptional start site is occupied by RNA 
polymerase II and a set of general transcription factors [46].  
The VACV K1 protein is a 31-kDa protein that possesses nine ankyrin repeat 
domains (ARDs) [33]. During virus infection, the presence of K1 correlates with the 
presence of IkBa and absence of NF-kB activation [56]. This implies that K1 acts at or 
upstream of IkBa [56]. K1 also inhibits PKR [69], a multifunctional cellular protein that 
activates NF-kB [71] in addition to PKR’s main role of inhibiting host cell translation 
[70].  Willis et al. went on to show that, during virus infection, PKR activation is the 
cause of NF-kB activation [68]. Thus, in the infected cell environment, K1 antagonizes 
PKR activation, and this upstream event is responsible for K1’s inhibition of NF-kB [68].   
Aravalli et al. show that ectopic K1 inhibits Toll-like receptor 2 (TLR2)-induced 
NF-kB activation [1] in primary murine macrophages. Although this may also involve 
PKR activation [7], it also raised the possibility that K1 may inhibit NF-kB in a PKR-
independent function. To further query if K1 indeed possesses an alternative strategy to 
antagonize NF-kB,  we used two strategies to uncouple PKR and NF-kB activation; we 
expressed K1 independently of infection and used reagents that minimized PKR 
activation. Using these systems, data revealed that K1 localized to the nucleus and 
prevented CBP/p300-induced RelA acetylation and RelA-CBP interactions.  
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2.2 Materials and Methods 
Cells and plasmids 
Human embryonic kidney 293T (293T) cells and human cervical carcinoma 
(HeLa) cells were obtained from the American Type Culture Collection (ATCC). HeLa 
cells in which >95% of PKR was knocked down (PKRKD) were obtained from Dr. 
Charles Samuel (Department of Molecular, Cellular and Developmental Biology, 
University of California Santa Barbara) and were characterized previously [72]. Cells 
were cultured in Eagle’s minimal essential media supplemented with 10% FBS, 2mM L-
glutamine, 100 U/mL penicillin and 100 µg/mL streptomycin. 
 Plasmid pHA-K1 consists of a hemagglutinin epitope-tagged K1L gene inserted 
into the pCI expression vector [68]. A plasmid encoding an IkBα dominant negative 
(DN) (pIkBαDN) was provided by Dr. Dean Ballard (Vanderbilt University) [52]. pV5-
M2 plasmid expresses a V5 epitope-tagged M2 protein [22]. Plasmids pNF-kBluc, pIL-
8luc and pIRF3luc encode the firefly luciferase gene under the control of a synthetic NF-
kB promoter (Promega), the IL-8 promoter [14] or four copies of the PRDIII promoter 
sequence specific for IRF3 [48], respectively.  Plasmid pRL-null encodes a promoter-less 
sea pansy luciferase gene (Promega). Plasmid pMyD88 was obtained from Dr. Richard 
Tapping (Department of Microbiology, University of Illinois). pcFLIPL was provided by 
J. Cohen (National Institutes of Health). Plasmid TBK1 was a kind gift of S. 
Balachandran (Fox Chase Center). Plasmid pGFP-RelA was provided by Dr. Lin Feng-
Chen (Department of Biochemistry, University of Illinois) [11]. A plasmid encoding an 
FLAG-tagged version of CBP protein (pFLAG-CBP) was obtained from Dr. David P. 
Lebrun (Queen’s University) [31]. Plasmid HA-p300 was obtained from Dr. Den Rock 
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(Department of Pathobiology, University of Illinois) [15]. All plasmids were transfected 
into cells using the TransIT reagent (Mirus) following manufacturer’s instructions.  
 
Luciferase assays 
A dual-reporter luciferase assay was performed to quantify NF-kB or IRF3 
activation in transfected cells using previously published protocols [21, 48, 49, 56]. 
Briefly, subconfluent cellular monolayers of 293T or HeLa cells in 12-well plates were 
transfected with 112.5 ng pNF-kBluc or pIL-8luc [14] or pIRF3 [21], 12.5 ng pRL-null 
and 1000 ng pCI, pIkBαDN, pFLAG-cFLIPL or pHA-K1. At 24 h later, cells were 
incubated in regular medium or medium containing tumor necrosis factor-a (TNF) (10 
ng/mL; Roche) or phorbol 12-myristate 13-acetate (PMA) (50 ng/mL; Sigma) for the 
indicated times. In some cases, NF-kB or IRF3 activation was instead triggered by co-
transfection of cells with plasmids containing MyD88 or TBK1 genes, respectively. All 
transfections were performed in triplicate. Cells were lysed in 1x passive lysis buffer 
(PLB; Promega) and lysates were analyzed for firefly and sea pansy luciferase activities. 
For each lysate, the ratio of firefly luciferase activity to sea pansy luciferase activity was 
calculated to correct for differences in transfection efficiencies.  The triplicates were 
averaged.  The resultant values were used to compare the expression of the firefly 
luciferase gene in stimulated cells to that present in unstimulated, pCI-transfected cells, 
whose value was set to one. Values are shown as mean ± S.D. The Student’s t-test was 
used to determine the statistical significance of inhibition of luciferase activity by K1 or 
dominant-negative IkBα proteins versus unstimulated, pCI-transfected cells. Statistically 
significant inhibition of luciferase activity is indicated by asterisks (*P < 0.05).   
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Protein expression levels in lysates from luciferase assays were analyzed by 
immunoblotting. Briefly, 30 µg of protein from each lysate was separated by using SDS-
PAGE and transferred to PVDF membranes.  Membranes were probed with mouse 
monoclonal anti-HA antibody (1:1,000; Sigma-Aldrich) or anti-PKR (1:1,000; Santa 
Cruz) and then HRP-conjugated goat anti-mouse IgG (1:5,000; Thermo Scientific) to 
detect K1 protein expression levels. Antibody-antigen reactions were detected by using 
chemilluminescence reagents (Thermo Scientific) and autoradiography.  
 
Quantitative reverse transcriptase PCR (RT-qPCR) 
Transcription of the IL-8, IkBa, IL-6 and b-actin genes in the presence or absence 
of K1 protein expression was evaluated by RT-qPCR. 293T or HeLa cells were seeded in 
6-well plates at 5x105 or 1x105 cells/well, respectively. Cells were transfected with the 
amounts of plasmids indicated in the figure legends in triplicate. After 24 h, cells were 
incubated for 4 h (293T) or 2 h (HeLa) with medium lacking or containing 20 ng/mL 
TNF. Alternatively, cells were co-transfected with pGFP-RelA (500 ng) and pHA-p300 
(500 ng) and 1000 ng pCI or pHA-K1 for 24 h prior to collection instead of using TNF as 
a stimulator of NF-kB activation.  Total RNA was extracted from cells using the RNeasy 
Mini kit (QIAGEN) following manufacturer’s instructions. 500 ng of RNA from each 
sample was incubated with oligo-dT and the M-MuLV Reverse Transcriptase (New 
England BioLabs). The reaction was incubated at 42°C for 60 min, and then terminated 
by heating at 85°C for 5 min. The resultant cDNA was diluted 1:5 in DNase and RNase 
free water. Then, two µl of diluted cDNA were used for quantitative PCR, using a 
Mastercycler realplex EP (Eppendorf) and SoFast EvaGreen Super Mix (BioRad) per 
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manufacturer’s instructions. qPCR was performed using the following program: 95°C for 
2 min; 40 cycles of 95°C for 5 s, 55°C for 10 s. Changes in expression level of each gene 
were calculated by the 2
(−ΔΔC(T)) method [34].  For normalization, b-actin mRNA 
quantities for each cDNA sample were measured, and then each value was normalized to 
that of unstimulated, pCI-transfected cells. Data are presented as means ± S.D. from a 
minimum of three independent experiments. The Student’s t-test was used to determine 
statistically significant differences in mRNA expression levels as compared to 
unstimulated, pCI-transfected cells. The following designed primers were used to detect 
β-Actin cDNA: (5’-AGTTGCGTTACACCCTTTCT-3’) and (5’-
ACCTTCACCGTTCCAGTTT-3’). Primers designed to detect IL-8 cDNA were (5’-
CCAAGGGCCAAGAGAATATC-3’) and (5’-GAGGTAAGATGGTGGCTAATAC-3’). 
Primers designed to detect IkBa cDNA were (5’-ATCAGCCCTCATTTTGTTGC-3’) 
and (5’-ACCACTGGGGTCAGTCACTC-3’). Primers (5’-
TGAGAGTAGTGAGGAACAAGC-3’) and (5’-CATTTGTGGTTGGGTCAGG-3’) 
were used to detect IL-6 cDNA. 
 
Immunoblotting 
Protein concentration of lysates (including lysates used for luciferase activity 
assays) was determined by bicinchoninic (BCA) assay (Pierce) with the exception of 
experiments in which cytoplasmic and nuclear fractions were assayed. In this case, the 
660 nm protein assay (Pierce) was used instead of the BCA assay. Regardless, for each 
experimental sample, an equal amount of protein from each lysate was electrophoretically 
separated using SDS-PAGE. Proteins were transferred to PVDF membranes, and 
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membranes were blocked in 5% (w/v) milk in Tris-Buffered Saline and Tween 20 
(TBST; 150 mM NaCl, 50 mM Tris base, 0.05% Tween 20) for at least 30 min at room 
temperature. Membranes were incubated in the primary and secondary antibodies listed 
below. Antibody reactions on membranes were detected by using chemiluminescence 
reagents (Amersham and Thermo Scientific) and autoradiography.  
For the detection of IkBα protein levels, subconfluent cellular monolayers of 
293T HeLa or PKRKD cells in 6-well plates were transfected with 2000 ng of either pCI 
or pHA-K1. At 24 h later, supernatants were aspirated and cells were incubated in fresh 
medium either lacking or containing TNF (10 ng/mL; Roche) for 15 or 30 min. Next, 
cellular monolayers were dislodged using trypsinization, and cells were collected by 
centrifugation.  Cellular pellets were suspended in cytoplasmic extract (CE) buffer 
containing HALT protease inhibitors for 15 min [45, 56]. Lysates were centrifuged and 
clarified supernatants were removed to fresh tubes. Ten µg of cytoplasmically-extracted 
protein from each sample was evaluated for IkBα protein levels by using immunoblotting, 
in which immunoblots were incubated with rabbit monoclonal anti-IkBα antibody 
(1:2,500; Cell Signaling) and then HRP-conjugated goat anti-rabbit IgG (1:10,000; 
CalBiotech). Blots were re-probed with rabbit monoclonal anti-β-actin antibody (1:5,000; 
Sigma) and then HRP-conjugated goat anti-rabbit IgG (1:10,000; CalBiotech). An 
additional, identical set of immunoblotted lysates was used to detect K1 protein 
expression, in which PVDF membranes containing 30 µg of protein from each sample 
were incubated with mouse monoclonal anti-HA antibody (1:1,000; Sigma-Aldrich) and 
then HRP-conjugated goat anti-mouse IgG (1:5,000; Thermo Scientific).  Acetylation of 
the RelA protein at residue 310 was detected as follows.  1 x 105 HeLa cells were 
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transfected with 250 or 500 ng of pGFP-RelA and pFLAG-CPB or pCI. In addition, cells 
were co-transfected with 1000 ng of pCI or pHA-K1. At 24 h later cellular monolayers 
were dislodged by trypsinization and collected by centrifugation (18,000 rcf x 1 min). 
Cellular pellets were resuspended and lysed in Acetyl Lysis Buffer (ALB; 25 mM Tris-
HCl pH 7.5, 250 mM NaCl, 1% NP-40, 1 mM EDTA) for 20 min on ice. Lysates were 
centrifuged (18,000 rcf x 10 min) and clarified supernatants were transferred to new tubes. 
Samples were analyzed by immunoblotting, in which membranes were incubated with 
rabbit monoclonal anti-acetyl NF-kB RelA (Lys310) antibody (1:1,000; Cell Signaling). 
The blot was reprobed with rabbit polyclonal anti-RelA antiserum (1:1,000; Santa Cruz) 
to detect unmodified RelA. A duplicate blot was probed with anti-HA antiserum to detect 
K1 protein expression and actin. CPB was detected in a separate blot using anti-CPB 
(1,1000; Cell Signaling). To detect RelA-CBP interactions, PKRKD cells  were 
transfected with  250 or 500 ng of pGFP-RelA and pFLAG-CPB or pCI. In addition, cells 
were co-transfected with 1000 ng of pCI, pHA-K1 or pV5-M2 plasmids using Trans-IT 
transfection reagent. At 24 h post-transfection, cells from 3 wells were lysed in 300 µl 
ALB. A portion of each clarified lysate was removed to a new tube and used to probe 
protein expression in cellular lysates. The remaining clarified lysates were incubated with 
anti-CBP antibodies (Cell Signaling) for 6 h. Then protein G –Sepharose beads (Life 
Technologies) were added to the mixture and incubated overnight at 4C.  Next, beads 
were washed in large volumes of ALB.  Beads were mixed with 2x sample buffer 
containing 2-mercaptoethanol and boiled for 5 min.  A portion of each 
immunoprecipitation reaction was separated by SDS-PAGE.  Proteins were transferred 
electrophoretically to PVDF membranes and membranes were probed with the indicated 
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antiserum described above. The M2 protein was detected using anti-V5 antibody 
(1:1,000; Millipore). 
 
Cytoplasmic and nuclear fractionations 
1 x 106 293T cells were transfected with 1500 ng of either pCI, pIkBαDN or 
pHA-K1. At 24 h after transfection, cells were incubated with medium lacking or 
containing TNF (20 ng/mL) for 15 or 30 min. Cellular monolayers were detached by 
trypsinization, collected by centrifugation and processed as described in a previous 
publication [56]. Cells were suspended in 50 µl CE buffer and incubated on ice for 15 
min. Lysates were centrifuged at 1,000 rcf for 5 min, and clarified supernatants were 
collected to new tubes. The remaining pellet was washed in 200 µl CE and centrifuged 
(1,000 rcf for 5 min) twice.  The nuclei-containing pellet was resuspended in 30 µl of 
nuclear extract (NE) buffer (20 mM HEPES, 0.4M NaCl, 1 mM EDTA pH 8.0, 1 mM 
EGTA pH 8.0, 25% glycerol) and incubated for 20 min on ice, vortexing samples every 
10 min. Samples were centrifuged for 10 min at 18,000 rcf. Supernatants (nuclear 
extracts) were collected and stored at -80°C. Both cytoplasmic and nuclear extracts were 
evaluated by immunoblotting for the following proteins: tubulin (mouse monoclonal anti-
tubulin antibody (1:5,000; Abcam), PARP (rabbit polyclonal anti-PARP-1 antibody; 
1:1,000 Santa Cruz), RelA (rabbit polyclonal anti-RelA antibody (1:5,000; Santa Cruz) or 
K1 (mouse monoclonal anti-HA antibody; 1:1,000; Sigma-Aldrich). 
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NF-kB-oligonucleotide (TransAM) binding assay  
To study NF-kB-DNA interactions, 293T cells were transfected with 1500 ng of 
pCI, pIkBαDN, or pHA-K1. After 24 h, cells were incubated with medium lacking or 
containing 20 ng/mL TNF for 30 or 60 min. Next, nuclei were isolated and nuclear 
extracted proteins were generated as described above. Five µg of nuclear extract was 
evaluated for the DNA binding activity of NF-kB by using the TransAM NF-kB RelA 
DNA-binding ELISA kit (Active Motif) following the manufacturer’s instructions. 
Nuclear extracts were added to a 96-well plate coated with immobilized oligonucleotides 
containing an NF-kB consensus site (5’-GGGACTTTCC-3’).  Wells were washed and 
then incubated with a solution containing a primary antibody recognizing the RelA 
subunit of the NF-kB heterodimer.  This antibody only recognizes the transcriptionally 
active form of RelA when complexed with DNA. Wells were washed and incubated with 
solution containing an HRP-conjugated secondary antibody. Wells were washed again 
and incubated with a developer solution provided with the kit. Reactions were analyzed 
by spectrophotometry at a wavelength of 450 nm. In addition, some wells had an excess 
amount of immobilized oligonucleotides containing either the regular (wild-type) or 
mutated NF-kB consensus sequence to evaluate non-specific binding of NF-kB in this 
system. Data shown are a representative experiment of at least 3 independent experiments, 
and each experiment was performed with 3 technical triplicates.  
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2.3 Results 
The K1 protein inhibits NF-kB activation independently of virus infection 
To examine if K1 inhibited NF-kB via a PKR-independent mechanism, K1 was 
expressed ectopically in cells as a strategy to uncouple PKR activation and NF-kB 
activation.  NF-kB transcriptional action was evaluated by using luciferase reporter 
assays. We used pNF-kBluc, a plasmid that contains five copies of a NF-kB consensus 
binding site to activate the transcription of the firefly luciferase reporter gene [56], Fig. 
1(a) and 1(b), or pIL-8luc, a plasmid in which the cellular IL-8 promoter was used to 
control the firefly luciferase reporter gene [14], as shown in Fig. 1(c). Controls included 
cells co-transfected with empty vector (pCI) or with a plasmid expressing a dominant 
negative IkBa molecule, a protein that cannot be phosphorylated by IKK and thus 
remains associated with NF-kB to prevent NF-kB activation [64].  
Figures 1(a) and 1(b) showed that K1 inhibited NF-kB activation induced by 
either TNF or MyD88 over-expression respectively, albeit to a lesser extent than the 
dominant negative IkBa molecule. Because TNF and MyD88-induced NF-kB signal 
transduction pathways overlap from the point of IKK activation and downwards, this 
implied that K1 may be inhibiting an event occurring post-IKK activation. K1 was stably 
expressed in cells  for the duration of the experiments, and K1 expression itself did not 
activate NF-kB. K1 also inhibited reporter activity of a luciferase gene controlled by the 
cellular IL-8 promoter, a promoter that contains an NF-kB binding site.  as shown in 
Figure 1(c). An additional luciferase assay was performed in which activation of the IRF3 
transcription factor was examined by over-expressing TBK1 [21]. As shown in Figure 
1(d), the presence of K1 did not inhibit IRF3 activation, showing that K1 specifically 
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targets NF-kB activation. The cFLIPL protein, which is known to inhibit IRF3 activation 
[21], was expressed in parallel to show that conditions were conducive for activating and 
detecting IRF3 transcriptional activation. 
 RT-qPCR was used to evaluate the transcription of the NF-kB-regulated 
interleukin-8 (IL-8) and interleukin-6 (IL-6) genes, as shown in Fig. 1(e) - 1(g), as an 
alternative measure of NF-kB activation. We were interested in examining IL-6 gene 
expression because Myskiw et al. reported that induction of IL-6 gene expression is PKR-
independent during virus infection [43], thus providing another opportunity to examine 
PKR-independent NF-kB activation.  TNF stimulated the transcription of the IL-8 and 
IL-6 genes, as expected. In contrast, IL-8 and IL-6 mRNA levels were significantly lower 
in K1-expressing 293T and HeLa cells, as shown in Figs. 1(e) and 1(f), respectively. IL-8 
and IL-6 gene expression was also reduced in cells expressing the dominant negative 
form of IkBa, as expected. IL-8 mRNA levels were also lower in HeLa cells, although 
this decrease was not statistically significant, Fig. 1(g).  These data demonstrated that 
ectopically expressed K1 inhibited NF-kB activation under different conditions and in 
more than one cell type.  
 
The K1 protein inhibits NF-kB activation in a PKR-independent manner  
To further test the possibility that K1 possesses a PKR-independent NF-kB 
inhibitory function, we compared NF-kB activation in normal HeLa cells or a HeLa cell 
line derivative (PKRKD) that reduces PKR protein levels by 95% [72]. Similar to data in 
Fig. 1(d), K1 inhibited TNF-induced NF-kB activation in normal HeLa cells. This same 
inhibition was observed in PKRKD cells, as shown in Fig. 2(b). We noticed that TNF 
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stimulation of luciferase activity was lower in PKRKD versus parental HeLa cells, and this 
is consistent with one report showing that PKR plays a role in the TNFR1-NF-kB 
signaling pathway [63].  
PMA was used as an alternative stimulator of NF-kB in Figs. 2(c) and 2(d) 
because it activates NF-kB independently of PKR [73]. We have confirmed PKR protein 
levels are reduced in PKRKD cells as compared to HeLa cells in Fig. 2(e), similar to ours 
and others’ observations [69, 72].  Indeed, PMA-induced luciferase activity levels were 
similar in HeLa and PKRKD cells demonstrating that the absence of PKR did not alter 
cellular responsiveness to PMA. Importantly, K1 continued to antagonize PMA-induced 
NF-kB activation to similar extents in both cell lines.  While, in some cases, K1 protein 
levels were slightly lower in stimulated versus unstimulated cells, K1 still inhibited 
luciferase activity. These data suggest that K1 inhibits NF-kB activation in a PKR-
independent mechanism.  
 
IkBα degradation occurs in the presence of K1  
 To characterize the portion of the NF-kB pathway that K1 was blocking, we 
initially examined the effect of K1 on IkBa degradation (Figure 3). Observations in 
Figures 1 and 2 suggested that using TNF to stimulate NF-kB would minimize PKR 
activation, and this system continued to be used.  It is well-known that TNF-TNFR1 
interactions trigger IkBa degradation rapidly in several cell lines [25]. This same 
temporal degradation was observed in pCI-transfected cells (Figure 3). Interestingly, K1 
did not block IkBa degradation in all three cell lines tested. This phenotype was 
surprising because a 2004 publication from our lab shows K1 prevents IkBa degradation 
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during virus infection [56]. Data in Figure 3, in addition to the data in Figures 1 and 2, 
strongly implied that K1 possessed an additional mechanism to inhibit NF-kB activation, 
and that this mechanism occurred after IkBa degradation.  
 
NF-kB translocates to the nucleus in the presence of K1 
IkBa degradation unmasks the nuclear localization sequence (NLS) of RelA, now 
allowing NF-kB to translocate to the nucleus [25]. Since K1 did not prevent IkBa 
degradation, a logical question was to ask if K1 prevented NF-kB nuclear trans-location. 
In this case, a cellular fractionation assay separating cytoplasmic and nuclear localized 
proteins was used to query if K1 affected NF-kB nuclear translocation. There was a 
visible increase in nuclear-localized RelA in TNF-treated versus unstimulated pCI-
transfected cells (Figure 4). This translocation event was inhibited when a dominant 
negative IkBa was over-expressed, an expected result because dominant-negative IkBa 
remains bound to NF-kB to inhibit RelA nuclear translocation [13]. However, K1 did not 
inhibit NF-kB migration to the nucleus. RelA-containing band densities were similar in 
nuclear extracts from pCI- versus pHA-K1-transfected cells. This implies that K1 does 
not inhibit NF-kB nuclear translocation. 
The localization of K1 also was examined. K1 was predicted to be a cytoplasmic 
protein because it has no obvious NLS signals. However, K1 proteins were observed in 
similar amounts in the cytoplasmic and nuclear extracts (Figure 4).  Amounts of K1 did 
not visibly change when cells were stimulated (Figure 4).  This suggested that K1 was not 
migrating into the nucleus as part of an NF-kB complex. These same extracts were also 
probed with antiserum recognizing b-tubulin and PARP proteins to demonstrate 
 53 
successful separation of nuclear from cytoplasmic proteins. Note that the expression of a 
dominant negative IkBa molecule greatly reduced RelA/p65 nuclear translocation. This 
was expected because the dominant negative IkBa cannot be phosphorylated and 
degraded.  This also demonstrated that K1’s inability to inhibit RelA nuclear 
translocation is not due to transfection inefficiency because all cells were transfected 
simultaneously and using the same protocol. 
 
K1 allows NF-kB to interact with an oligonucleotide containing NF-kB binding sites 
Data from Figure 4 suggested that the antagonistic mechanism of K1 could be 
associated with K1’s nuclear localization. In the nucleus, NF-kB binds to a conserved 
DNA sequence present in the promoter of its target genes. The TransAM assay is one 
method to detect and quantitatively measure transcriptionally active NF-kB-DNA 
interactions (Figure 5). As expected, TNF treatment significantly increased NF-kB-DNA 
interactions, as demonstrated by the increase in values for the assay. This event was 
blocked in cells over-expressing a dominant-negative form of IkBa.  However, K1 did 
not inhibit NF-kB DNA interactions. This signal was specific for NF-kB because the 
signal decreased if an excess of oligonucleotides containing wild-type NF-kB consensus 
sites was present (WT competitor), but not when an excess of oligonucleotides with 
mutant NF-kB binding sites (mutant competitor) were present. Note that these controls, 
where excess WT or mutant competitor nucleotides were present, only were added to 
lysates from pCI-transfected cells that received 30 min TNF treatment.  
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K1 inhibits CBP/p300-mediated NF-kB activation and prevents RelA acetylation 
 The above data suggested that K1 allowed NF-kB to enter into the nucleus and 
interact with its promoter but inhibited NF-kB transcriptional activation.  One 
explanation for this pattern would be if K1 inhibited RelA acetylation, a post-
translational modification required for NF-kB activation. This modification is performed 
by the CBP/p300 family of proteins [23]. To test this hypothesis, we first asked if K1 
could inhibit NF-kB activation triggered by over-expression of RelA and p300, 
conditions known to induce NF-kB activation [23]. K1 inhibited NF-kB activation, as 
measured by expression of the NF-kB regulated IL-8 and IkBa genes, as shown in Figs. 
6 (a) and 6 (b) respectively.  These data support the hypothesis that K1 acts at or 
downstream of RelA acetylation.   
CBP, like its p300 ortholog, binds to and acetylates RelA at lysine 310 [42]. This 
can occur either before or after NF-kB interacts with kB binding sites in a promoter [42]. 
To ask if K1 prevented this post-translational modification, RelA and CBP were over-
expressed to trigger and detect RelA acetylation [10].  This approach was chosen because 
it has proven difficult by us and others to detect acetylation of endogenous RelA [10]. As 
expected, acetylation at lysine 310 was observed in pCI-transfected cells, as shown in 
Figure 6 (c). However, this acetylation was greatly reduced in K1-expressing cells. This 
was observed in both HeLa (Fig. 6 c) and PKRKD cells (Fig. 6 d). It was also observed 
that K1 protein levels slightly decreased when increased amounts of plasmids RelA and 
CBP were present. Nevertheless, K1 still inhibited RelA acetylation. Thus, data in Figure 
6 support the hypothesis that K1 targets RelA acetylation to prevent NF-kB activation in 
a PKR-independent mechanism. 
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 One possibility for this lack of RelA acetylation would be due to a lack of CBP-
RelA interactions in K1-expressing cells. To test this possibility PKRKD cells were 
examined for RelA-CBP interactions using co-immunoprecipitations, using the same 
conditions in Figure 6 (c).  Results are shown in Figure 6 (d). In vector-transfected cells, 
RelA-CBP interactions were detected when RelA and CBP were over-expressed. This 
interaction was greatly reduced when the K1 protein was present.  This was a specific 
property of K1 because the expression of another poxviral NF-kB inhibitory protein (M2) 
did not inhibit this interaction and did not inhibit RelA acetylation (Fig. 6 e)[22]. M2 is 
not expected to inhibit RelA-CBP interactions because M2 interferes with MEK-directed 
phosphorylation of ERK2, a kinase that targets the IKK complex for NF-kB activation 
[22], thus acting on a signal transduction step prior to RelA-CBP interactions. Multiple 
attempts were made to co-immunoprecipitate K1 with RelA or with CBP under several 
different conditions.  However, under no conditions tested could we reproducibly detect 
such interactions. 
 
2.4 Discussion  
Several pieces of data indicate that K1 inhibits NF-kB activation in a PKR-
independent manner. K1 retained its NF-kB inhibitory function when using stimuli that 
do not trigger PKR activation (e.g., PMA or co-expression of RelA and CBP/p300) or 
using a cell line with dramatically decreased PKR levels. Since K1 allowed IkBa 
degradation and NF-kB nuclear translocation, it was likely that K1 prevented a signal 
transduction event that occurs after these events. There are two lines of evidence that K1 
targets RelA acetylation. First, K1 inhibited RelA/p300-induced luciferase reporter gene 
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expression. Second, K1 inhibited p300-induced acetylation of RelA. It was also observed 
that RelA-CBP co-immunoprecipitations no longer occurred in the presence of K1, 
suggesting that K1 prevents interactions of proteins necessary for NF-kB activation. 
Unfortunately, we could not reliably detect K1-RelA or K1-CBP interactions in 
eukaryotic cells by co-immunoprecipitations.  Thus, we cannot rule out the possibility 
that K1 may act indirectly to prevent RelA-CBP interactions. 
Interestingly, K1 did not prevent NF-kB from binding to oligonucleotides 
containing kB-binding sites. Originally, it was thought that CBP/p300 interacts with NF-
kB prior to NF-kB binding to its consensus DNA sequence.  However, a recent 
publication from Mukherjee et al. shows that there is a higher preponderance of 
promoters constitutively loaded with CBP/p300 [42]. One such gene found to be 
controlled by this latter mechanism is IkBa, a gene we examined here. Thus, one model 
based on these data is that K1 allows NF-kB to bind to its promoter sequence, but then 
prevents p300/CBP from interacting with NF-kB. Mukherjee did not report whether the 
IL-8 gene, an additional gene we examined, was controlled in a similar manner.  Thus, 
whether K1 acts in a similar manner or via a different mechanism remains the focus of 
future studies.  
K1 possesses 9 ankyrin repeat domains (ARDs) [33]. These 33-residue repeats are 
important for mediating protein-protein interactions in other ARD-containing proteins 
[32, 40].  Two viral ARD-containing proteins that inhibit NF-kB are African Swine Fever 
Virus (ASFV) A238 and cowpox CP77 proteins [9, 50], and they bind to RelA. However, 
two lines of evidence suggest K1 does not interact with RelA.  First, we did not observe 
increase nuclear K1 protein levels in TNF-treated cells, implying that K1 does not enter 
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the nucleus as an NF-kB binding partners. Second, we do not consistently observe K1-
RelA co-immunoprecipitations in pHA-K1-transfected cells. It should be noted that the 
Orf poxvirus 002 protein also inhibits RelA acetylation by binding to RelA [15].  
However, Orf 002 lacks ARDs, suggesting that K1 and Orf 002 share functional 
similarities despite lacking similarity at the amino acid level [15]. 
Along with K1, there are other viral ARD proteins (vankyrins) encoded by 
poxviruses, herpesviruses and polydnaviruses [3, 17, 27]. Most of the poxvirus vankyrins 
also possess an additional F-box motif [27] (referred to as a PRANC domain) [27]. This 
F-box motif allows these poxviral ARDs to bind to Skp1, a member of the E3 SCF 
ubiquitin ligase complex. This occurs for multiple proteins encoded by ectromelia virus 
(EVM002, EVM005, EVM154 and EVM165) [5, 65], Orf virus (OV008, OV123, OV126, 
OV128, OV129) [59], myxoma virus (M-T5, M148, M149, M150) [67], vaccinia virus 
68k [60], fowlpox virus FPV014 [6], monkeypox virus 003 [39], variola virus G1R [39], 
and  cowpox virus proteins CP77 [9] and CPXV006 [39]. For the ectromelia virus 
proteins with PRANC domains, this interaction with Skp1 is sufficient to antagonize the 
normal ubiquitination function of the SCF E3 ligase complex and inhibit IkBa 
degradation [5]. K1 is unique in that it does not possess a partial or full F-box motif. This 
implies that K1 cannot interfere with IkBa ubiquitination, a hypothesis supported by the 
observation that K1 allowed IkBa degradation. Interestingly, the variola virus G1R, 
cowpox virus 006, ectromelia EVM002, and monkeypox virus 003 ANK/F-box proteins 
also bind to and cleave p105 to prevent formation of the RelA/p50 complex [39]. It is 
unlikely that K1 targets p105 processing because NF-kB still binds to an oligonucleotide 
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containing kB binding sites (Fig. 5), suggesting that a functional RelA/p50 complex is in 
the nucleus. 
Here, we show that K1 inhibits RelA acetylation and RelA-CBP interactions, 
suggesting that K1 performs its inhibitory function in the nucleus. VACV encodes 
multiple inhibitors of NF-kB including M2, A46, A52, K7, B14, N1, C4, A49 and E3 [4, 
12, 16, 19, 22, 35, 43, 53, 56]. Most of these proteins act prior to NF-kB nuclear 
translocation. For example, M2, A46, A52, K7 and E3 proteins inhibit cytoplasmic 
proteins that stimulate IKK [4, 22, 43, 44, 53]. B14 binds to cytoplasmic IKK and inhibits 
its activation [12]. N1 has also been reported to interact with the IKK complex [16]. 
However, this interaction has been disputed [12]. Similarly, C4 acts at a step at or 
downstream of IKK activation but prior to NF-kB nuclear translocation [19]. A49 
prevents IkBa ubiquitination and degradation by binding to cytoplasmic bTcRP [35]. 
Thus, K1 is the first VACV protein to act in the nucleus to prevent NF-kB activation. K1 
is unique also because the other known NF-kB inhibitory proteins expressed by VACV 
do not possess ARDs [58]. It should be noted that Sumner et al. reported that an as-yet-
unidentified early VACV protein inhibits an NF-kB signal transduction event that occurs 
post-RelA nuclear translocation [62]. The construct used for their studies (vv811DA49) 
lacks K1L, suggesting that K1 may not be the sole VACV protein that has antagonistic 
function in the nucleus.   
The sub-cellular location of K1 was studied here for the first time. It was present 
in both the cytoplasm and nucleus of unstimulated and stimulated cells. Because K1 is a 
small protein (31 kDa), it may be able to enter the nucleus by diffusion [66].  No obvious 
nuclear localization sequence (NLS) is present in K1.  Two other ARD-containing 
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proteins (myxoma virus M150 protein and cellular IkBa) use an ARD repeat to localize 
to the nucleus [8]. Thus, a similar mechanism for K1 may be present, which is a future 
direction for our research.  
K1 was identified as a host range gene over 30 years ago [18, 47]. Other functions 
have been ascribed to K1, including binding to the VACV C10 protein [36], ACAP2 [38], 
and SAMD9 [57]. K1 also inhibits PKR activation [68, 69], and inhibits a cellular factor 
whose expression is controlled by IRF1 [37]. These functions map to different regions of 
K1. For example, K1 residues 47, 51, 82, 83 and 85 are important for vaccinia virus 
replication in HeLa cells, a cell line where either K1 or C7 is sufficient for virus 
replication [33, 38]. A mutant K1 that no longer allowed virus replication (mutations at 
residues 82, 83, 85; S2C#2) still interacted with ACAP2, showing that these two 
molecular functions of K1 were not related to each other [38]. A future direction of our 
work is to identify the K1 region responsible for RelA acetylation as a means to better 
understand how K1 inhibits RelA activation.  
The ARD is one of the most abundant motifs in nature [40], and these motifs are 
the basis for protein-protein interactions that control a variety of cellular signal 
transduction pathways and functions. ARDs are 33-residues in length, comprising two 
short a-helices which are connected by b-turns [40]. Sequential ARDs in proteins then 
stack together. Unlike enzymes, ARD-containing proteins do not recognize specific 
sequences in their target proteins. Instead, their ability to bind to a certain protein is due 
to the orientation of ARDs that, when stacked together, form a surface that exposes a 
binding site unique for its target protein [32]. The solving of the crystal structure of K1 
revealed novel aspects of this viral ARD in contrast to cellular ARD proteins [33]. 
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Namely, the residues critical for K1’s host range function are exposed on the convex 
surface of its ANK repeats [33]. This makes K1 unusual; all other ARDs use residues in 
the concave surface to interact with binding partners. DARPINS (new design ANK repeat 
proteins) are being explored as a novel alternative strategy to monoclonal antibodies to 
treat diseases such as measles and HIV [20, 54]. DARPINs are an attractive alternative to 
antibodies as they provide several advantages including absence of aggregation, high 
stability, smaller size and simpler architecture, low cost production [61].   Thus, the 
continued exploration of ARDs like K1 may provide a rational basis for improving 
DARPINS. 
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2.5 Figures 
 
Figure 2.1 The K1 protein inhibits NF-kB activation when expressed independently 
of infection. (a-d) Luciferase activity detecting NF-kB or IRF3 activation in 293T cells 
transiently co-transfected with 1000 ng of either empty vector (pCI), pIkBaDN, pHA-K1 
or pcFLIPL. Cells were also co-transfected with 12.5 ng pRL-null and 112.5 ng of (a, b) 
pNF-kBluc, (c) pIL8luc or (d) pIRF3luc. (b) Cells were co-transfected with an additional 
500 ng pCI or pMyD88.  At 24 h post-transfection, cells were incubated in regular 
medium (UN) or medium containing 10 ng/mL TNF for 2 h.  Cellular lysates were 
evaluated for luciferase activities. (d) Luciferase activity detecting IRF3 activation in 
293T cells transiently co-transfected with 1000 ng of either empty vector (pCI), pcFLIPL 
or pHA-K1. In this case, cells were also co-transfected with the reporter plasmids above 
and 500 ng pCI or pTBK for 24 h [21]. Results are presented as the fold-induction of 
luciferase activity relative to those of unstimulated, pCI-transfected cells. Lysates were 
also examined for HA-tagged K1 protein expression. Quantitative RT-PCR analysis of 
IL-8, IL-6 and b-actin mRNA from (e) 293T or (f, g) HeLa cells that were transfected for 
24 h with 1500 ng pCI, pHA-K1 or pIkBaDN and then treated with 20 ng/mL TNF for 
(e) 4 h, (f) 1 h or (g) 2 h.  Results are presented as IL-8 or IL-6 cDNA relative to b-actin 
cDNA for each sample, and recorded as relative to those of untreated, pCI-transfected 
cells. These experiments are a representative of experiments performed at least three 
times. *P < 0.05, compared with unstimulated, pCI-transfected cells.  
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Figure 2.2 K1 inhibits NF-kB activation in a PKR-independent manner. HeLa or 
PKRKD cells were transfected for 24 h with luciferase reporter plasmids (125 ng pNF-
kBluc, 12.5 ng pRL-null) and 1000 ng pCI, pIkBaDN or pHA-K1. Next, cells were 
incubated in regular medium (UN) or medium containing (a) and (b) 10 ng/mL TNF for 2 
h or (c) and (d) 50 ng/mL PMA for 8 h. Results are presented as fold-induction of 
luciferase activity relative to those of untreated, pCI-transfected cells. Lysates were also 
examined for HA-K1 protein expression. (e) PKR protein levels in HeLa and PKRKD cell 
lysates.  These experiments are a representative of experiments performed at least three 
times. *P < 0.05, compared with unstimulated, pCI-transfected cells.  
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Figure 2.3 IkBa degradation occurs in the presence of K1. (a) 293T (b) HeLa or (c) 
PKRKD cells were transfected with 2000 ng of pCI or pHA-K1 for 24 h prior to 
incubation with regular medium (UN) or medium containing 10 ng/mL TNF for 15 or 30 
min. Cellular lysates were separated by SDS-PAGE and then transferred to PVDF 
membranes.  Membranes were probed with anti-IkBa antibodies, and then the same blots 
were re-probed with anti-b-actin antiserum. A separated set of immunoblotted proteins 
was used to detect HA-K1 protein levels. These experiments are a representative of 
experiments performed at least three times. 
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Figure 2.4 NF-kB translocation to the nucleus occurs in the presence of K1. 293T 
cells were transfected for 24 h with 1500 ng pCI, pIkBaDN or pHA-K1. Cells were 
incubated in medium either lacking (UN) or containing TNF (20 ng/mL) for 30 or 60 min, 
and then lysed in a manner that separated cytoplasmic from nuclear proteins. A portion of 
extracts containing cytoplasmic or nuclear proteins was probed for the presence of the 
RelA subunit of the NF-kB heterodimer by using immunoblotting. The same samples 
were also probed for the presence of K1 proteins by immunoblotting. Each sample was 
also probed with anti-b-tubulin and anti-PARP antibodies to serve as markers of 
cytoplasmic content and nuclear content, respectively. These experiments are a 
representative of experiments performed at least three times. 
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Figure 2.5 The K1 protein allows NF-kB-DNA interactions.  ELISA-based analysis of 
the binding activity of nuclearly-localized NF-kB in 293T cells transfected with pCI, 
pIkBaDN or pHA-K1. At 24 h post-transfection, cells remained either unstimulated 
(UN) or stimulated with 20 ng/mL TNF for 30 or 60 min.  Cells were lysed and nuclei 
were isolated.  Proteins from isolated nuclei were incubated in 96-well plates containing 
immobilized oligonucleotides containing consensus NF-kB binding sites.  For the 
extracts collected from pCI-transfected cells after 30 min TNF treatment, extracts were 
incubated with an excess of oligonucleotides containing a wild type NF-kB consensus 
sequence (WT competitor) or a mutated consensus sequence (Mutant Competitor) to 
confirm the specificity of the assay. These oligonucleotides were not added to extracts 
from cells treated for 60 min with TNF. Regardless, all wells were subsequently 
incubated with a primary antibody specific for the active form of RelA and an HRP-
conjugated secondary antibody. Reactions were quantified by using spectroscopy. Data 
represent the optical density (OD) average of 3 replicates. These experiments are a 
representative of experiments performed at least three times. 
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Figure 2.6  The K1 protein inhibits p300/CBP-mediated NF-kB activation and RelA 
acetylation and RelA-CBP interactions.  (a and b) Quantitative RT-PCR (qPCR) 
analysis of IL-8, IkBa and b-actin mRNA. HeLa cells were co-transfected with 500 ng 
pCI, pGFP-RelA and pHA-p300 and 1000 ng pCI, pIkBaDN or pHA-K1.  At 24h post-
transfection, mRNA from lysed cells was reverse-transcribed to cDNA and cDNA was 
analyzed by using qPCR. Results are presented as (a) IL-8 or (b) IkBa cDNA relative to 
b-actin cDNA expression for each sample, and recorded as relative to those of 
unstimulated, pCI-transfected cells. *P < 0.05, compared with unstimulated cells 
transfected with pCI. (c) HeLa or (d and e) PKRKD cell lines were transfected with pCI or 
250 or 500 ng pGFP-RelA and pFLAG-CBP and co-transfected with 1000 ng pCI, pHA-
K1 or pV5-M2. (c - e) Lysates were probed for the acetyl-RelA (ac-RelA) subunit of NF-
kB. The same blots were reprobed with anti-RelA antiserums. A separated set of 
immunoblotted proteins was used to examine CBP and K1 or M2. (d and e) Co-
immunoprecipitation of CBP and RelA. Cells were lysed in ALB and clarified lysates 
were incubated with anti-CPB antibody and protein G-sepahrose beads.  A portion of 
each lysate prior to immunoprecipitations was saved and used to detect protein 
expression levels. Beads were washed and then subjected to immunoblotting.  Blots were 
probed with anti-RelA. These experiments are a representative of experiments performed 
at least three times. 
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Chapter 3: Deletion of the K1L gene results in a vaccinia virus that is less pathogenic 
due to muted innate immune responses, yet still elicits protective immunity 
3.1 Introduction 
Vaccinia virus (VACV) is a large, double-stranded DNA virus that encodes nearly 
200 genes [45]. VACV was used as the vaccine to eradicate smallpox. The continued 
study of VACV remains important because there are reports of VACV infections in 
animals and humans [15, 33, 58]. Moreover, VACV derivatives are now being used as 
vectors for vaccines against other infectious diseases and as oncolytic virotherapy [54].  
The vaccinia K1 protein is an intracellular 31-kDa protein encoded by the K1L 
gene. K1L was initially described as a host range factor because its expression is required 
for VACV replication in rabbit and hamster cell lines [19, 48]. It is now known that K1 
possesses other functions that antagonize the immune response. K1 is known to 
antagonize NF-kB [10, 57], PKR [76, 77], IRF1 [42] and type I IFN [44]  signal 
transduction pathways. There are several cellular and viral binding partners of K1, 
including the vaccinia C10 protein [41], and the cellular ACAP2 [8] and SAMD9 
proteins [59]. However, it is not clear how such interactions may aid in K1 immune 
evasion. K1 possesses 9 ankyrin repeat domains (ARDs), motifs that mediate protein-
protein interactions [34].  While poxviruses encode multiple ARD proteins [29], K1 lacks 
a C-terminal F-box present in nearly all other poxvirus ARDs [29]. This suggests that K1 
may have physiological properties unique from other poxviral ARDs. 
Despite this vast knowledge of K1, only one publication examines the role of K1 
in pathogenesis [38]. Liu et al. show that deletion of the K1L gene attenuates VACV 
strain TianTan as measured by weight loss and neurovirulence in intradermal and 
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intracranial routes of infection [38]. Unfortunately, the parental strain used by Liu et al. 
lacked additional genes involved in vaccinia virus immune evasion (A53R, C12L) or 
morphogenesis (A33L) [38], making it difficult to assess the specific contributions of K1 
to VACV pathogenesis.  
To fill this gap in knowledge, the contribution of the K1L gene to viral 
pathogenicity was examined here by deleting only the K1L gene (vDK1L) from VACV 
western reserve (WR) strain, the strain that is most often used for pathogenesis studies 
[60]. We show here that a virus lacking the K1L gene was less pathogenic than the 
parental VACV strain WR (designated vK1L) when using either the intranasal (IN) or 
intradermal (ID) ear pinnae inoculation models of infection [72, 75]. The ID model of 
infection was then further investigated because it is argued that, in humans and in mice, 
intradermal infection of the skin comes closest to the most relevant natural route of 
infection with VACV [33].  Interestingly, vDK1L replicated to the same extent as vK1L, 
suggesting that pathogenicity was not due to diminished viral loads. Instead, the 
decreased pathogenicity of vDK1L correlated with a diminished leukocyte infiltration and 
muted immune gene expression to infection in ears, as measured by flow cytometry and 
RT-qPCR, respectively. These results suggested that the decreased pathogenicity of 
vDK1L was due to a muted immune response, which in turn strengthens the concept that 
immunopathology plays a role in poxvirus-induced diseases. Despite this muted response 
by components of the innate immune response, vDK1L infection still induced VACV-
specific CD8+ T cells and protected against a lethal VACV challenge. Thus, vDK1L had a 
decreased pathogenicity that nevertheless stimulated protective immune responses. 
vDK1L may be a valuable tool to further understand the relationship between viral 
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pathogenesis, viral modulation of innate immunity and stimulation of protective immune 
responses. 
 
3.2 Materials and Methods 
Viruses and cells 
Vaccinia virus strain Western Reserve (referred to as vK1L in this manuscript) 
and vDK1L were obtained from Dr. Bernard Moss (Laboratory of Viral Disease, National 
Institutes of Health). vDK1L was described previously; it is a Western Reserve (WR) 
virus in which the K1L gene was replaced with the E. coli gpt gene by homologous 
recombination [57]. vK1Lrev is a recombinant virus in which the WR K1L gene was re-
inserted into vDK1L at its natural locus.  To create vK1Lrev, a DNA amplicon containing 
the entire K1L gene and flanking regions was PCR amplified from WR DNA using 
oligonucleotide primers (5’-GGGATATTAAGTGCATAGCC-3’) and (5’-
CCGGAAGATCGCTATCG-3’). vK1Lrev was generated by homologous recombination, 
in which the K1L gene replaced the E. coli gpt gene. RK13 cells, which are non-
permissive for vDK1L infection [68], were infected with vDK1L and then transfected 
with the K1L-containing amplicon.  Thus, only recombinant viruses now stably 
expressing the K1L gene are expected to replicate in RK13 cells [63].  Inoculated cellular 
monolayers were incubated for 48 h and progeny viruses were isolated by plaque picking 
and subjected to four rounds of purification. The correct insertion of K1L was verified by 
using PCR analysis of purified viral genomes from recombinant viruses, using two 
primer sets (5’-CGGTTCCCATGATGAACGTAG-3’) and (5’-
CCCATAGAACATCAGTCTCC-3’) and (5’-CATGCCGTCATGCTTAATG-3’) and 
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(5’-TCACGCCATAACTACCACG-3’). In addition, verification of the presence of K1L 
gene in vK1Lrev viruses were PCR amplified using (5’-
GGGATATTAAGTGCATAGCC-3’) and (5’-CCGGAAGATCGCTATCG-3’), and the 
resultant amplicon was sequence analyzed. vDK1LDC7L, which lacks both the K1L and 
C7L genes, was obtained from Dr. Yan Xiang (University of Texas Health Science 
Center)[43]. 
Vero, BSC-1, mouse embryo fibroblasts (MEFs) and RK13 cells were cultured in 
Eagle’s minimal essential media (MEM) supplemented with 10% FBS and 2mM L-
glutamine. Virus medium (MEM supplemented with 2.5% FBS) was used for virus 
absorption phases and for virus infections. Viruses used for inoculation of mice were 
purified by sucrose density gradient centrifugation. 
 
In vitro growth curves 
 One-step and multi-step growth curves were performed as follows. Confluent 
MEF cellular monolayers were infected with vK1L, vDK1L, vK1Lrev or vDK1LDC7L at 
a multiplicity of infection (MOI) of 0.01 or 10 PFU/cell. After the initial absorption 
phase, cellular monolayers were washed three times to remove unattached viruses. At the 
indicated times post-infection, cellular supernatants were removed to a new tube.  
Supernatants were subjected to centrifugation (800 x g for 10 min at 4°C) and cell-free 
supernatants were transferred to new tubes. Cellular monolayers were collected by 
scraping into 1 ml virus medium.  Samples were centrifuged at 800 x g for 10 min at 4°C. 
Cellular pellets were resuspended in 1 ml of virus medium. For all samples, cells or 
supernatants were lysed by freeze-thawing three times.  Samples were sonicated to 
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release virions from cellular debris. Cellular lysates or supernatants were serially diluted, 
and 0.5 ml of each dilution was inoculated onto Vero cell monolayers in duplicate.  At 48 
h later, plaques were visualized by staining cellular monolayers with a crystal violet dye-
based solution. Data are expressed as the mean titer per sample +/- SEM. 
 
Murine intranasal and intradermal models of infection 
 Female BALB/c and C57BL/6 mice (6-8 weeks old) were purchased from The 
Jackson Laboratory (Bar Harbor, ME) and housed in AAALAC-approved ABL-2 
facilities at the University of Illinois at Urbana-Champaign (UIUC). All animal 
experiments and procedures were approved by the Institutional Animal Care and Use 
Committee at the UIUC. 
 For intranasal (IN) inoculations, BALB/c mice (n = 5 per group) were 
anesthetized by isofluorane (5% in O2) inhalation using a vaporizer unit (Vetland, 
Louisville, KY).  Mice were inoculated with 104 or 105 PFU in 20 µl (10 µl per nostril) of 
vK1L, vDK1L, vK1Lrev or PBS. Mice were weighed and monitored for signs of illness 
daily as a means to evaluate severity of infection [69]. Weight data were expressed as the 
percentage of the mean of each individual animal’s weight loss from day 0. Mice that lost 
more than 25% of their original weight were euthanized. A clinical score for each mouse 
was assigned daily, based on a metric published by Berhanu et al [6] to assess sickness.  
Briefly, the scoring was: 0 = normal; 1 = slightly ruffled fur; 2 = significantly ruffled fur; 
3 = score 2 combined with hunched posture and/or conjunctivitis; 4 = score 3 combined 
with difficulty breathing, socializing and/or moving; and 5 = death. Clinical scores are 
expressed as the mean of each group.  
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 For intradermal (ID) inoculations, anesthetized C57BL/6 mice (n = 5 per group) 
were inoculated ID in the left ear dorsal pinna with 104 PFU of vK1L, vDK1L, or 
vK1Lrev in a 10 µl volume using a Hamilton syringe (Reno, NV) and 27-gauge needle as 
described previously [71, 72]. Infected ears were examined daily for the next 21 days for 
the presence of lesions. The lesion size was measured by using a 0.01 mm digital caliper 
(Neiko Tools, Homewood, IL). Lesion size is expressed as the mean of the group +/-  
SEM. 
 In some cases, ID-inoculated mice were challenged with a lethal dose of vaccinia 
virus as a model for protective vaccination [32].  Here, C57BL/6 mice (n = 5 per group) 
were inoculated ID as described above with PBS or 104 PFU of vK1L or vDK1L. At 30 
days post-infection, mice were inoculated IN with vK1L (5 x 106 PFU) in a 20 µl 
volume, and mice were weighed daily for 7 days post-infection. Weight data were 
expressed as the percentage of the mean of each individual animal’s weight loss from day 
0. Mice that lost more than 25% of their original weight were euthanized. 
 
Virus titers in tissues 
To assess virus replication in organs after IN inoculations, organs (brains, lungs, 
spleens) were harvested at 2, 4 and 6 d post infection (pi)(n = 5 mice per experimental 
group).  Organs were flash-frozen in liquid nitrogen. Whole organs were thawed on ice, 
weighed, and then homogenized in 0.5 ml of virus medium using a 1 ml Dounce 
homogenizer (Wheaton, Millville NJ). Homogenates were subjected to three freeze-thaw 
cycles and sonicated. Lysates were serially diluted and 0.5 ml of a dilution was used to 
inoculate Vero cellular monolayers in duplicate. At 48 h later, viral titers were detected 
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by plaque assays. Virus titers are expressed as the amount of infectious virus per gram of 
tissue.  
To determine virus replication during ID infections, ears were harvested at 1, 3, 5, 
8, or 11 d post-infection (n = 5 mice per experimental group) and flash frozen in liquid 
nitrogen. Ears were thawed on ice, weighed and placed in 2 ml RB sample tubes (Qiagen, 
Valencia, CA) with 0.5 ml of virus media and a sterile 7 mm stainless steel bead (Qiagen, 
Valencia, CA). Samples were subjected to two homogenization rounds at 50 Hz for 3 min 
using a TissueLyser LT (Qiagen, Valencia, CA). Lysates were serially diluted, and 0.5 ml 
of a dilution was used to inoculate Vero cellular monolayers in duplicate. At 48 h later, 
viral titers were detected by plaque assays. Virus titers were expressed as the amount of 
infectious virus per gram of tissue.  
 
RT-qPCR analysis of host genes from infected ears 
 Left ears were inoculated ID with vK1L, vDK1L, vK1Lrev or PBS (n = 4 mice 
per group) as described above. Ears were collected at 1, 3 or 5 d post-infection and flash 
frozen in liquid nitrogen. Each frozen ear was cut into two equal parts, and each piece 
was placed into a sterile tube that previously was incubated in a dry ice/ethanol bath for 
15 min to minimize RNA degradation. Each tube also contained a sterile 7 mm stainless 
steel bead (Qiagen, Valencia, CA). Next, tubes were placed in the TissueLyser LT 
(Qiagen, Valencia, CA) for 2 min at room temperature prior to adding 0.6 ml of RLT 
lysis buffer containing 1% 2-mercaptoethanol to each tube. Samples were homogenized 
using the TissueLyser LT at 50 Hz for 3 min at room temperature. Tubes were then 
mixed by inverting, and subjected to another round of homogenization. Homogenates 
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from each ear half were combined into one tube and centrifuged at 18,000 x g for 3 min. 
Supernatants were transferred to new tubes and one volume of 70% ethanol was added. 
Total RNA was extracted from samples using the Qiagen RNeasy kit (Qiagen, Valencia, 
CA). RNA was quantified and the integrity of the RNA was assessed by using a 48 
capillary Fragment Analyzer (Advanced Analytical Technologies, Ankeny, IA).  
 Two µg of RNA from each ear sample was reverse transcribed to cDNA as 
follows.  Briefly, total RNA was incubated with 0.5 µg of oligo dT primer (IDT, 
Coralville, IA) and (M-MulV) Reverse Transcriptase (New England BioLabs, Ipswitch, 
MA) at 70° C for 5 min, followed by a 5 min incubation at 4°C, as per manufacturer’s 
instructions. cDNA was submitted to the Carver Biotechnology Center at the University 
of Illinois at Urbana-Champaign for further analyses. Briefly, all cDNA samples 
underwent standard target amplification, in which 1.25 µl of cDNA was incubated with 
2.5 µl 2X TaqMan PreAmp Master Mix (Thermo Fisher) and 0.5 µl 0.2X TaqMan primer 
probe mix (Thermo Fisher). The primer probes used are as follows: ccl4 
(Mm00443111_m1), cxcl2 (Mm00436450_m1), cxcl5 (Mm00436451_g1), ccl2 
(Mm00441242_m1), ccl5 (Mm01302427_m1), cxcl9 (Mm00434946_m1), cxcl10 
(Mm00445235_m1), cxcl1 (Mm04207460_m1), il1b (Mm00434228_m1), il6 
(Mm00446190_m1), il10 (Mm01288386_m1), il7 (Mm01295803_m1), tnf 
(Mm00443258_m1), ifng (Mm01168134_m1), ifna4 (Mm00833969_s1), ifnb 
(Mm00439552_s1), isg15 (Mm01705338_s1), Rnase1 (Mm00712008_m1), mx1 
(Mm00487796_m1), eif2ak2 (Mm01235643_m1), krt6a (Mm00833464_g1), krt16 
(Mm01306670_g1), nfkb2 (Mm00479807_m1), nfkbia (Mm00477798_m1), gapdh 
(Mm99999915_g1). Reactions were incubated at 95°C for 10 min, followed by 14 cycles 
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of 95°C for 15 sec and 60°C for 4 min using the MJ Research Tetrad thermal cycler (MJ 
Research, Waltham, MA). A portion of each reaction was then incubated with TaqMan 
FAM-MGB probes specific for each mouse gene shown in Table 1 (Thermo Fisher 
Scientific). Aliquots (5 µl) of each sample were loaded onto a Fluidigm 48.48 Dynamic 
Array integrated fluidic circuit (IFC) chip (Fluidigm) according to manufacturer’s 
directions. qPCR was performed in a Biomark HD Real-Time PCR (Fluidigm) using the 
following thermal conditions: 70°C for 30 min, 25°C for 10 min, 95°C for 1 min, 
followed by 35 cycles of 96°C for 5 sec and 60°C for 20 sec. 
Analysis of data was performed using Fluidigm Real Time PCR Analysis version 4.1.3. 
The averaged mRNA expression (fold-induction) per group was quantified by calculating 
the 2-DDCT value for each ear and then averaging these values, with values from time-
matched mice inoculated with PBS as the calibrator for each day, and GAPDH or HPRT1 
(data not shown) as the reference gene.  Values were compared between ears infected with 
vK1L versus vDK1L, or PBS versus vK1L, or PBS versus vDK1L, or PBS versus vK1Lrev. 
 
Ultrasound analysis of ID-inoculated mouse ears 
C57BL/6 mice were inoculated ID with vK1L, vDK1L or PBS or not inoculated 
as described above. All mice were anesthetized using isofluorane and ears were imaged 
with the VisualSonics Vevo2100 (VisualSonics, Toronto, CA) high-frequency ultrasonic 
imaging system, using the MS-550S linear array, in dorsal recumbency at the days 
indicated post-infection. The Vevo2100 acquired the raw radio-frequency (RF) image 
data from which (off-line) B-mode images were processed from each ear, and from those 
images, the ear thicknesses were estimated. Also from each B-mode image, a Field of 
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Interest (FOI; pink line in Fig. 6A) was manually segmented to denote the region where 
the backscatter coefficient (BSC) was estimated and represented as a color-coded BSC 
image. The BSC is a quantitative ultrasound (QUS) measure of the B-mode echo 
strength. To generate the BSC image, the FOI was divided into 75%-overlapped sub-
Regions of Interest (sub-ROIs) with dimensions 193 µm x 193 µm (equivalent to 4 x 4 
wavelengths at 32 MHz). For each sub-ROI a BSC value was estimated using the 
reference phantom technique [37, 78], thus yielding a BSC versus ultrasonic frequency 
curve. Each sub-ROI’s BSC value was generated by averaging BSC over the frequency 
range from 25 to 43 MHz, denoted BSC (25-43 MHz), with a color then assigned to each 
BSC (25-43 MHz) value. To represent each ear with a single BSC value, all the sub-ROI 
BSC image values within the FOI were averaged (averaged over space, spatial average); 
these single BSC values were averaged and then graphically represented. The thickness 
of the ear was selected from the spatially calibrated BSC image (Fig. 6A) for which the 
pixel dimension was known (68 x 68 pixels = 1 mm x 1 mm). The number of pixels was 
estimated in the region of the BSC image that depicted the thickest measure of the color-
coded image. 
 
Histopathology  
 C57BL/6 mice were inoculated ID with vK1L, vDK1L or PBS or not inoculated 
as described above. Mice (n = 3 per group) were euthanized on days 3, 4, or 5 post-
infection. Ears were collected and fixed in 10% neutral buffered formalin. Three sections 
of each ear were taken from the inoculation site and routinely processed, paraffin-
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embedded, sectioned, deparaffinized and stained with hematoxylin and eosin. 
Representative microscopic images are shown. 
 
Analysis of immune cell infiltration in infected ears  
 Female C57BL/6 mice were inoculated ID in the left ear with vK1Lrev, vDK1L or 
PBS as described above (n = 7 for vK1L, n = 7 for vDK1L; n = 10 for PBS). Mice were 
euthanized on day 5 post-infection. Each inoculated ear was collected and the dorsal and 
ventral sheets were separated with forceps, and incubated with type I collagenase (3 
mg/mL; Worthington Biochemicals, Lakewood, NJ) and deoxyribonuclease I (1.25 
U/mL; Worthington Biochemicals, Lakewood, NJ) for 1 hr at 37° C. Each sample was 
then passed through a 70 µm nylon cell strainer to produce single cell suspensions. Cells 
from each ear were counted via trypan blue exclusion to determine total number of cells 
per ear and to ensure cellular viability. Because so few immune cells were present from 
each PBS-inoculated ear, cells from PBS-inoculated ears were combined to have enough 
cells for sufficient analyses. For the rest of the ears, there were sufficient immune cells, 
and cells from each ear were kept separate. The pooled cells from PBS-inoculated ears or 
cells from each infected ear were incubated with Fc-block (Biolegend, San Diego, CA) 
for 15 min, and then incubated  in a solution of antibodies in the presence of Fc-block and 
10% mouse serum (Jackson ImmunoResearch, West Grove, PA) for 1 hr. Antibodies 
were CD45-eFluor450 (clone 30-F11; 1:400; eBioscience, Waltham, MA), CD11b-PE 
(clone M1/70; 1:200; BioLegend, San Diego, CA), CD11c-Alexa488 (clone N418; 1:100; 
BioLegend), Ly6C-Alexa700 (clone AL-21; 1:200; BD Bioscience, San Jose, CA) and 
Ly6G-PECy7 (clone 1A8; 1:200; BD Bioscience). All sample acquisition and 
 84 
compensation was performed using a BD LSRII flow cytometer (BD Bioscience). Data 
were analyzed with FCS Express Software (DeNovo Software, Version 5, Glendale, CA). 
Events were gated on live cells using forward vs. side scatter. Dead cells were excluded 
on the basis of atypical fluorescence. Fluorescence minus one (FMO) was used to aid in 
gating of appropriate cellular populations. Leukocytes were identified as CD45+. We 
defined tissue-protective monocytes as CD45+CD11b+CD11c-LyC6+Ly6G+. 
Inflammatory monocytes were defined as CD45+CD11b+CD11c-LyC6+Ly6G- cells. 
CD45+CD11c+ cells were also investigated, and these cells include dendritic cells, NK 
cells and activated T cells. To account for the fact that there were different number of 
total cellular infiltrates obtained from PBS- vs. vK1Lrev- vs. vDK1L-infected ears, the 
percent populations of different immune cells were then multiplied by the number of total 
cells per ear to obtain total number of each immune cell population examined per ear. 
Data were expressed as the mean number of cells +/- SEM per ear.  
 
Detection of VACV-specific, IFN-g expressing CD8+ T cells 
 C57BL/6 mice were inoculated ID with vK1L, vDK1L or PBS (n = 5 mice per 
experimental group) as described above. At 10 d post-infection, mice were euthanized 
and spleens and livers were harvested. Single-cell suspension of spleens and lymph nodes 
were prepared as follows. Spleens were forced through a 70 µM nylon mesh (Thermo 
Fisher Scientific, Waltham, MA) and then erythrocytes were removed by treating sample 
with ACK red cell lysis buffer. Lymph nodes were homogenized by using a BioMasher II 
disposable microtube homogenizer (Research Products International, Mt. Prospect, IL).  
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Single cell suspensions (106 cells) of spleens or lymph nodes from each animal 
were kept separate, and cells from each spleen or lymph node were either unstimulated or 
stimulated with VACV-specific peptide (TSYKFESV; B8R20-27 epitope) for 4 hours in 
the presence of Brefeldin A (5 µg/mL; Sigma, St. Louis, MO). Using this approach, only 
CD8+ T cells recognizing VACV peptides would become activated. Then, cells were 
stained with FITC-conjugated anti-CD8 antibody (clone 53-6.7; 1:100; BioLegend) in 
Cell Staining Buffer (BioLegend, San Diego, CA) for 30 min on ice to stimulate VACV-
specific T cells. Next, samples were fixed for 20 min at room temperature and 
permeabilized on ice in fixation and intracellular staining permeabilization buffer 
(BioLegend, San Diego, CA), respectively. Cells were stained for intracellular IFN-g as a 
marker of T cell activation by incubating fixed cells with Alexa 647-conjugated anti-IFN-
g (clone XMG1.2; 1:100; BioLegend, San Diego, CA) overnight at 4° C. Samples were 
washed in permeabilization buffer. Flow cytometry was performed with a BD Accuri C6 
cytometer (BD Bioscience, San Jose, CA), and data was analyzed with FCS Express 
Software (DeNovo Software, Version 5, Glendale, CA). Events were gated for live 
lymphocytes on forward versus side scatter. Dead cells were excluded on the basis of 
atypical fluorescence. Data were expressed as the percentage of IFNg+CD8+ T cells, cells 
that are considered VACV-specific and activated, out of all CD8+ T cells.  In addition, 
data were expressed as the total number of IFNg+CD8+ T cells per lymph node or spleen. 
 
Statistical analysis  
To determine statistically significant differences between weight loss and lesion 
sizes during vK1L and vDK1L infection, two-way ANOVA followed by Tukey’s 
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multiple comparisons test was performed. For viral replication in the lungs, brain and 
spleen, the non-parametric Kruskal-Wallis test followed by Dunn’s multiple comparison 
test was used to determine statistically significant difference between vK1L and vDK1L. 
To determine statistical significant differences in immune cell infiltration between 
vK1Lrev and vDK1L one-way ANOVA or Kruskal-Wallis test followed by Tukey’s or 
Dunn’s multiple comparison tests, respectively, was performed. For the analyses of RT-
qPCR assays, one-way ANOVA was used to determine if there were statistically 
significant differences between ears infected with vK1L versus vDK1L, or PBS versus 
vK1L, or PBS versus vDK1L, or PBS versus vK1Lrev. To determine if there were 
statistically significant differences in T cell responses between vK1L and vDK1L a one-
way ANOVA followed by Tukey’s multiple comparisons test was performed. All 
analyses were executed using GraphPad Prism software (La Jolla, California). 
 
3.3 Results 
The K1 protein is not essential for replication in mouse cells in vitro  
The goal here was to identify the contribution of K1L to viral pathogenesis in a 
mouse model of infection.  A vaccinia virus deleted for the K1L gene (vDK1L) replicates 
to the same extent as wild-type vaccinia virus (vK1L) in several human and non-human 
primate cell lines [48, 68] but is compromised when replicating in a hamster and a rabbit 
cell line (e.g. BHK-21 and RK13)[51, 68]. However, it is not known if K1L is a host 
range factor in mouse cells.  
Since the goal was to determine the contribution of K1L on virus pathogenicity in 
a mouse model of infection, an important question to ask is if the K1L gene is required 
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for virus replication in mouse cells. To answer this question, virus growth was 
characterized in mouse embryo fibroblasts (MEFs)(Figure 1). MEFs were infected with a 
high MOI (10 PFU/cell) to examine a virus replication during a one-step growth curve or 
a low MOI (0.01 PFU/cell) to examine virus replication and spread during a multi-step 
growth curve.  Infectious viruses present in either cells or cell-free supernatants were 
quantified by using plaque assays (Figure 1). In all cases, vDK1L replicated to the same 
levels as vK1L using either one-step (Figures 1A and 1B) or multi-step growth curve 
assays (Figures 1C and 1D). A revertant virus in which the K1L gene was stably re-
inserted into vDK1L (vK1Lrev) was also tested. As expected, this virus had growth 
properties similar to vK1L (Fig. 1). For all experiments, an additional virus lacking both 
the K1L and C7L genes (vDK1LDC7L) was examined as a control. vDK1LDC7L does 
not replicate in the murine NIH 3T3 cell line [42].  In a similar manner, this same virus 
replicated to lower levels than viruses containing C7L in MEFs (Figure 1).  In summary, 
these data suggest that K1L is not a host range factor for murine cells. 
 
The K1L gene contributes to pathogenicity in an intranasal mouse model   
Liu et al. report that the deletion of K1L from vaccinia virus strain TianTan 
(VTTDK1L) decreases virus pathogenicity [38]. However, it is difficult to appreciate the 
full impact of the K1L gene on pathogenicity using this virus background because 
VTTDK1L has different properties than vDK1L: VTTDK1L replicates poorly in HeLa 
cells [38] while the WR-based vDK1L does not [48, 68]. This may be due to the fact that 
the parental and K1L-less construct used by Liu et al. lacked three additional genes 
involved in vaccinia virus immune evasion (A53R, C12L) and morphogenesis (A33L) 
 88 
[38], which may have unknown effects on virus pathogenicity. To overcome this 
problem, our approach was to use a WR strain of vaccinia virus in which only the K1L 
gene was absent (vDK1L). This allowed the examination of the pathogenic effect of the 
K1L gene without the confounding effects of the absence of other virus genes. WR was 
chosen as the vaccinia virus strain for study because it is most frequently used for 
pathogenesis studies in mice [60].   
For wild-type vaccinia virus (vK1L), intranasal (IN) inoculation provides a 
system to evaluate viral pathogenesis in which weight loss and clinical signs of illness 
indicate the relative pathogenicity of a virus [1, 53]. Typically, mice are inoculated with 
104 PFU of wild-type VACV (vK1L) and examined daily. Under such conditions, vK1L 
caused weight loss and clinical signs of illness similar to results reported by Alcami and 
Smith (Figure 2A)[1]. In contrast, vDK1L-infected mice lost less weight (Figure 2A). 
Statistically significant differences in weight between vK1L and vDK1L were observed 
on days 5-7 pi. Additionally, vDK1L-infected mice, but not vK1L-infected mice returned 
to their original weight by 14 d pi, suggesting that mice fully recovered from vDK1L 
infection. The re-insertion of K1L into vDK1L (vK1Lrev) resulted in a virus with a 
pathogenicity similar to vK1L, indicating that the K1L gene was responsible for this 
decreased pathogenicity (Figure 2A). When data were charted as a Kaplan-Meir survival 
curve, all mice infected with vK1L or vK1Lrev were euthanized due to weight loss by 8 
days pi (Figure 2B). In contrast, all vDK1L-infected mice survived. 
Signs of illness were also examined daily and quantified based on a 5-point 
scoring system that is used determine the extent of sickness caused by a poxvirus [2, 6]. 
Notably, there was a 2-day delay before illness onset in mice infected with a virus devoid 
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of K1L versus K1L-containing viruses. In addition, the signs of clinical illness were 
decreased in vDK1L-infected mice as compared to mice infected with K1L-containing 
viruses (Figure 2C). As expected, mice inoculated with PBS showed no signs of weight 
loss or illness at any time point.  Together these data suggest that a virus devoid of the 
K1L gene is less pathogenic than its wild-type parental virus. 
This experiment was repeated using more stringent conditions, namely a 10-fold 
higher dose (105 PFU) of virus (Figures 2D-F). Again, vDK1L was less pathogenic than 
K1L-containing viruses.  Several differences were noticed when comparing the weights 
of vDK1L-infected mice receiving 105 versus 104 PFU (Figure 2D).  First, mice receiving 
105 PFU vDK1L lost more weight at earlier times pi as compared to those inoculated with 
104 PFU. Second, vDK1L-infected mice did not return to their original weights by 14 
days pi. In addition, one vDK1L-infected mouse was euthanized due to weight loss 
(Figures 2D and 2E). These differences are likely due to the fact that an increased dose of 
virus increases the pathogenic effects of a virus [2]. Indeed, when mice received the 
higher inoculum of 105 PFU, signs of illness occurred earlier in all mice. However, signs 
of illness were significantly reduced in mice infected with vDK1L versus K1L-containing 
viruses (Figure 2F).  Thus, data from Figure 2 show that K1L itself is a virulence factor in 
an IN model of infection. In summary, data from Figure 2 show that vDK1L has 
decreased pathogenicity as compared to wild-type vaccinia virus. 
 
K1L contributes to virus replication in vivo 
Often, a decrease in virus pathogenicity correlates with decreased virus 
replication in mouse organs [5, 13, 20, 21, 40, 66]. Data in Figure 3 showed that this 
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trend also occurred for vDK1L in the IN infection route. For example, vDK1L titers in 
lungs were approximately 10-fold lower than vK1L on day 2 pi, and approximately 100-
fold lower than vK1L on days 4 and 6 pi (Fig 3A).  
During an IN infection, WR initially replicates in the lungs. Next, VACV 
disseminates to the brains, and then spreads to distal organs such as the spleen and 
ovaries [2, 53]. Because vDK1L titers were decreased in the lungs, it was not surprising 
that vDK1L titers also were lower than vK1L in the brains (Figure 3B). Note that only 
one mouse brain had detectable vK1L or vK1Lrev titers on day 2 pi, while two mouse 
brains possessed vDK1L viruses (Figure 3B). This was expected because VACV 
routinely is not detected in mouse brains until 3 days pi [53]. By day 6 pi, all mouse 
brains had detectable titers of vK1L or vK1Lrev. However, vDK1L titers were 200-fold 
lower as compared to vK1L. No viruses were detected in spleens at 2 days pi (Fig. 3C), 
reflective of the fact that wild-type VACV is only detectable in spleens as early as 3 days 
pi [53]. Thus, it was not surprising that no viruses were detected in spleens at 2 days pi 
(Fig. 3C). While all virus titers increased rapidly by day 4 pi (Figure 3C), vDK1L titers 
were approximately 100-fold lower than vK1L titers.  All virus titers were lower in 
spleens by day 6 pi and this is similar to patterns observed by others [1, 53]. Thus, in the 
IN model of infection, the reduced pathogenicity of vDK1L correlated with a decrease in 
vDK1L virus replication.  
 
The K1 protein contributes to pathogenicity in an intradermal model of infection  
The intradermal (ID) inoculation of a mouse ear pinna provides a second model to 
evaluate vDK1L pathogenicity [36, 72]. The ID infection model has many strengths to 
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study how VACV modulates host immune response. It closely resembles the scarification 
route used during smallpox vaccinations, and is most similar to the locale (skin) of 
infection for other poxviruses including molluscum contagiosum virus and Orf [52, 61]. 
Here, lesion formation and size is an indicator of pathogenicity [71].  Unlike the IN route 
of infection, ID inoculation is localized [72]. Thus, there are no generalized clinical signs 
of illness like those observed during IN infections (e.g. weight loss or fur ruffling), and 
there is little to no virus detection in distal organs [72]. Figure 4 shows results using this 
model system. For all viruses tested, gross lesions were observed starting on day seven pi 
for all viruses. vK1L or vK1rev infection induced the largest lesion at days 12 and 8, 
respectively (Fig. 4). In contrast, lesions were smaller in vDK1L-infected ears at all times 
examined. These differences were statistically significant on days 7-12 and 14-16 pi. 
Thus, K1 also contributed to pathogenicity for the ID model of infection. 
 
Decreased lesion size is not due to diminished virus replication in the ID infection  
Data from the IN model of infection showed that decreased pathogenicity of 
vDK1L was associated with its decreased replication in the lungs (Figure 3).  Thus, a 
logical assumption was that virus titers would be lower in vDK1L-infected ears. 
Surprisingly, this premise did not hold true; Figure 5 showed that there were no 
statistically significant differences in virus titers between viruses containing or lacking 
the K1L gene at any time point examined (Figure 5).  This included time points where 
there was no lesion formation (days 1 and 3 pi), just prior to visible lesion formation (day 
5 pi), and times where lesions had formed and remained attached to ears (days 8 and 11 
pi). These last two time points were chosen to minimize the possibility that, if there were 
 92 
a decrease in virus titers, it would not be due to a loss of virus encrusted in lesions. These 
data showed two important trends. First, lesion size did not correlate with virus 
replication, which was opposite of the results observed in the IN infection model. Second, 
since vDK1L replicated to similar levels as vK1L in pinnae, K1L was not a host range 
gene in mouse ear pinnae.  
 
Examination of edema during infection   
We continued studies with the ID infection system but not with IN infection 
system.  This is because there are numerous examples of mutant VACV that lack NF-kB 
antagonists where a decrease in viral pathogenesis correlates with a decrease in virus 
replication in lungs and other organs (e.g.; DA49, DC4, DE3, DK7) [5, 9, 20, 40]. In 
contrast, there is only one other published example of a mutant VACV that lacks the NF-
kB inhibitor B7 (DB7R) where viral pathogenesis is not due to virus replication [50]. 
Thus, the continued study of vDK1L in ear pinnae would be more likely to uncover novel 
aspects of virus-host interactions. 
The ID model of infection relies on the visual detection of lesion formation to 
assess virus pathogenicity [72]. ID infection of ears causes inflammation [17, 22, 30, 31]. 
Thus, we were curious if edema, a classical sign of inflammation, was accelerated or 
delayed during vDK1L infection.  Immune responses prior to lesion formation use 
terminal procedures (e.g., histopathology) to examine tissue damage and are semi-
quantitative [17, 22, 30, 31]. In contrast, ultrasound imaging successfully quantified 
inflammation for processes like fatty liver disease [25]. A benefit of this technology is 
 93 
that it is non-invasive and allows scientists to quantitatively track progression of disease 
in the same mouse.  
 We chose to use ultrasound as a means of asking if early signs of inflammation 
(e.g. edema) were different in infected ears. Ultrasound was used to collect B-mode 
images for each ear. The region in pink contains ear tissue while the substrate used for 
ear placement is shown as a gray platform under the ear (Figure 6A, left hand panel). The 
pink field of interest was then used for quantitative ultrasound backscatter coefficient 
(BSC) data assessment (Figure 6A, right hand panel). As fluid concentration (edema) 
increases in an ear, the ultrasonic scattering magnitude decreases [49]. This is quantified 
as a decrease in ultrasonic backscatter coefficient (BSC), and this change can be 
quantified using QUS technology [49] and displayed in graphical form (Fig. 6B). The 
BSC color-coding represents the quantitative magnitude of the gray-scale B-mode echo 
data. The color-coded scale on the right is in logarithmic units, in which red is related to 
the highest BSC value and the lowest fluid content, while dark blue is related to the 
lowest BSC value and the highest fluid content.  Increase in fluid content for this study is 
edema, confirmed by histopathology. Edema is triggered by early inflammatory 
signaling. The BSC values from each mouse ear were determined, and measurements 
from each ear were averaged and yielded a mean +/- SEM (Figure 6B)[49].  
Uninoculated and PBS-inoculated ears are color-coded in red, implying that there 
is little to no fluid infiltration (Figure 6A) resulting in high BSC values (Fig. 6B). 
Infection with vK1L or vDK1L showed an increase in edema longitudinally, with the 
most noticeable differences beginning on day 3 pi and continuing until day 5 pi (Figure 
6A), and BSC values decreased during these times (Figure 6B). Overall, there was a 
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statistically significant decrease in BSC between virus-infected ears versus PBS- or 
uninoculated ears (Fig. 6B) at days 4 and 5 pi. vDK1L infection result in a slight decrease 
in BSC values as compared to vK1L, however this was not statistically significant (Fig. 
6B). Thus, vDK1L infection minimally affected edema.  
The thickness of each ear was digitally measured as another means of assessing 
inflammation. The number of pixels was estimated in the region of the BSC image that 
depicted the thickest measure of the color-coded image. Data are shown in Figure 6C. 
Thicknesses of vDK1L-infected ears were similar to vK1L-infected ears on days 1-3 pi. 
The largest difference in ear thickness between vK1L and vDK1L infections occurred on 
day 4 pi, in which there was an approximately 0.2 mm difference in thickness.  However, 
this difference decreased by day 5 pi, where vDK1L-infected ears were nearly the same 
thickness as vK1L-infected cells. Thus, while vDK1L-infected ears were less thick than 
vK1L-infected ears, these differences in ear thickness appears to be transient. 
Some mouse ears used for ultrasound imaging were processed further for 
histological examination using hematoxylin and eosin (H & E) staining to evaluate tissue 
morphology (Figure 7). Examination of the architecture of the ear tissue showed that, at 
day 3 pi, both vDK1L and vK1L -infection resulted in mild edema. A single mouse of the 
vK1L-infection group had a small focal region of more pronounced inflammation. By 
day 4 pi, both vDK1L- and vK1L-infected ears exhibited similar pinna thickening and 
this was primarily due to moderate dermal edema. Ear thickening was also due to 
hyperplasia with ballooning degeneration and pustules in the epidermis. By day 5 pi, 
microscopic lesion formation was prominent in both vDK1L- and vK1L-infected ears and 
lesions were progressed in severity, with some ulceration and crusting. vDK1L infection 
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had less extent of the lesions in the pinna (Figure 7). This correlates with differences in 
lesion sizes shown in Figure 6C. Overall, there was a moderate and transient decrease in 
edema in vDK1L infected ears versus vK1L at all times examined. Thus, classical 
histopathology showed trends similar to quantitative ultrasound imaging, suggesting 
quantitative ultrasound technology is a new non-invasive technology to detect 
inflammation.  
vDK1L infection results in decreased immune cell infiltration 
Figure 5 showed that, unlike results from the IN infection model, the decreased 
lesion size observed in vDK1L-infected ears was not due to decreased viral replication. 
Another mutant VACV that lacks the B14 NF-kB antagonist VACV (vDB14R) enhances 
the infiltration of immune cells as compared to wild-type VACV during an ID infection 
[11]. This suggested that an enhanced host inflammatory response may contribute to 
diminished lesion size.  
To test if this also was the basis for reduced lesion sizes for vDK1L-infected ears, 
we used flow cytometry to detect and quantify immune cell types that are known to 
infiltrate the ear upon VACV infection [22, 32]. The presence of these innate immune 
cells was examined at day 5 post-infection. This time point was chosen because viral 
replication was robust, and it is a time where it is known that these types of innate 
immune cells would be detectable in infected ears [22].  Results are show in Figure 8.  
The first striking result was that there were dramatically less (4.3 times less) 
cellular infiltrates harvested from vDK1L-infected versus vK1Lrev-infected ears (Figure 
8A). However, the number of infiltrates in vDK1L-infected ears was 3 times higher than 
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PBS-inoculated ears. This implied that vDK1L infection indeed drew some immune cells 
into the area of infection, but this number was diminished as compared to vK1L-infected 
ears.  
We were then interested in examining the number and types of infiltrating 
leukocytes in ears.  Because the total number of cells varied between the groups of PBS-, 
vK1Lrev- and vDK1L-infected ears, we could not represent data as the percent 
population of total cells.  Instead, data in Figures 8B-E were presented as the total 
number of each cell population per ear to allow for better comparisons. When examining 
CD45+ (leukocyte) infiltration, there were 4.7 times more CD45+ cells in vK1Lrev- 
versus vDK1L-infected ears (Figure 8B).  The number of infiltrates in vDK1L-infected 
ears was 3 times higher than PBS-inoculated ears, indicating that vDK1L infection was 
not inert. 
We investigated the relative abundance of three subsets of CD45+ leukocytes that 
are reported to be detectable in infected ears 5 d pi [22, 32]. Data are shown in Figures 
8C-E. These include tissue-protective monocytes; CD45+CD11b+CD11c-LyC6+Ly6G+) 
and inflammatory monocytes (CD45+CD11b+CD11c-LyC6+Ly6G-)[22, 32]. 
CD45+CD11c+ cells were also investigated which can include dendritic cells, NK cells 
and activated T cells.  There were dramatic decreases in all three cell types examined in 
vDK1L- versus vK1Lrev-infected ears. Again, CD11c+, LyC6+Ly6G+ and LyC6+Ly6G- 
cell numbers were higher in vDK1L- versus PBS-inoculated ears, suggesting that vDK1L 
infection elicited a moderate infiltration of leukocytes. These data showed a correlation 
between a reduced lesion size and reduced immune cell infiltrates, implying that 
infiltrating immune cells may produce molecules that promote immunopathology. 
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vDK1L infection results in a muted host immune gene expression profile 
 In cell culture, vDK1L infection resulted in an increased transcription of an NF-
kB-controlled gene (TNF) as compared to vK1L infection [57]. Thus, one hypothesis was 
that the expression of immune genes under the control of NF-kB (e.g., cytokines and 
chemokines) would occur earlier and/or to a greater extent in vDK1L- versus vK1L-
infected ears. Results from Figure 8 showed that there was a decrease in infiltration of 
leukocytes during vDK1L infection. Since leukocytes migrate to areas expressing 
chemokines and other cytokines, this raised an alternative hypothesis: that the expression 
of cytokines and chemokines would be decreased during vDK1L infection. To test both 
hypotheses simultaneously, we evaluated the transcription profile of 24 host cell genes at 
days 1, 3 and 5 pi in ears inoculated ID with either PBS, vK1L, vDK1L or vK1Lrev using 
RT-qPCR. These time points were chosen for two reasons.  First, it afforded the 
opportunity to examine if host immune genes were transcribed in vDK1L-infected ears 
before vK1L-infected ears. Second, these time points harvested ears prior to lesion 
formation, therefore minimizing potential RNA loss due to scab formation. Gene 
expression values from infected mice were normalized to PBS-inoculated mice 
euthanized on the same day.  Statistical analyses were performed comparing PBS- to 
vK1L-infected or vK1L- to vDK1L-infected ears. 
Results from these studies are shown in Table 1. Several striking trends were 
observed.  First, there was no statistically significant difference in gene expression 
between vK1L and vDK1L-inoculated ears at 1 day pi. These results opposed the first 
hypothesis that, in the absence of an NF-kB antagonist, there would be an increase in the 
expression of NF-kB controlled host genes during vDK1L infection.  
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By day 3 pi, there was a more robust host response to vK1L infection. Notably, 
there was a statistically significant induction of Cxcl1 and Il6 gene expression. Il10 
mRNA levels were also statistically significantly increased, in agreement with data 
published by Cush et al [16]. While not statistically significant, there was a 9-fold 
increase in Cxcl10 gene expression in vK1L-infected ears, also in agreement with a 
previous publication [30]. We observed that vK1Lrev-infected ears showed a slightly 
more robust response to virus infection in several instances for reasons that remain 
unclear. For example, Cxcl5, Isg15, Mx1, Eif2ak2 (PKR) and Krt6a mRNA levels were 
significantly higher in vK1Lrev- as compared to PBS-inoculated mice. Unexpectedly, 
vDK1L-infected ears showed a different pattern of host gene expression. Nearly all the 
mRNAs examined were lower in vDK1L-infected ears as compared to vK1L-infected 
ears. Thus, in contrast to what was expected, removal of K1L led to a decrease in the 
expression of anti-viral genes during infection. 
 vK1L or vK1Lrev infection continued to stimulate host gene transcription at day 
5 pi, and this increase was statistically significant as compared to PBS-inoculated ears in 
most cases. As reported by others, we detected upregulation of Ccl4, Cxcl9, Ifng, Il1, Il6 
and Mx1 in VACV-inoculated ears, suggesting these are important cytokines to detect 
and resolve VACV infection [17, 30].The exceptions to this trend were for transcription 
of the Il7, Tnf, Ifna4, Ifnb, Nfkb2 and Nfkbia genes, which were either similar to or lower 
than values obtained for infections at 1 day pi.  Others have also reported the lack of Tnf 
and type I IFN gene expression during VACV infection [30]. However, IFN gene 
expression more recently has been detected by other researchers who have optimized 
RNA purification protocols (Dr. Chris Norbury, personal communication).  
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When examining vDK1L-infected ears at day 5 pi, there were several noticeable 
trends.  Most of the host cell transcripts were lower in vDK1L- versus vK1L-infected 
ears. This result was surprising because it was the opposite of our original hypothesis. 
The greatest reduction for expression of the Ccl4 gene, with a 12.4-fold reduction of 
mRNA for vDK1L versus vK1L infected mice, followed by Ifng with a 7.6-fold 
reduction.  Other genes in which there was a statistically significant reduction of mRNA 
levels in vDK1L- compared to vK1- infected mice also included Cxcl2 and Cxcl5 (5.2-
fold), Il1b (4.6-fold), Cxcl9 (3.5-fold), Il10 (3.3-fold), Rnasel (2.2-fold) and ccl2 (2.0-
fold). There were several instances in which there were differences in gene expression, 
but these differences were not statistically significant due to variance among the mice 
within the groups. These genes included the chemokine Ccl5 and Cxcl10 genes, the Il6 
gene, the interferon-stimulated Mx1 and Isg15 genes, and the keratinocytes stress 
response genes Krt6a and Krt16. As mentioned earlier, K1 antagonizes type I IFN [44] 
and NF-kB [10, 57]. Interestingly, genes encoding a type I IFN (Ifnb) or NF-kB-
controlled genes (Nfkbia and tnf) [14, 28, 56, 67]  showed no K1L-dependent change in 
expression. However, other genes at least partially controlled by NF-kB (Ifna4, Il7 and 
Nfkb2) showed significant down-regulation in the absence of K1L [35, 39]. For Nfkb2, the 
mRNA was slightly, but significantly higher in vDK1L- versus vK1L-infected mice. 
There was only one gene, Cxcl1, which mRNA expression was slightly higher in vDK1L- 
vs vK1L-infected mice, however this difference was not statistically significant. Thus, 
there were two conclusions drawn from these data. First, the decreased expression of 
immune response genes correlated with a decrease in leukocytes infiltration and a smaller 
lesion size. Second, vDK1L counterintuitively dampened pro-inflammatory gene 
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expression. Many of these pro-inflammatory molecules also induce immunopathology. 
Thus, vDK1L-induced lesions may be smaller because of the diminished expression of 
these pro-inflammatory cytokines.   
 
vDK1L infection activates VACV-specific CD8+ T cells    
We observed that vDK1L infection was less pathogenic. In addition, the 
infiltration of leukocytes and expression of immune response genes was lower in vDK1L- 
versus vK1L-infected mice. We were curious to ask if this decreased host response would 
also result in a diminished capacity to trigger a protective immune response. To answer 
this question, we examined vaccinia-specific, activated CD8+ T cells from the spleens 
and lymph nodes of infected mice (Fig. 9A-D). In spleens, virus infection significantly 
increased the number of activated (IFN-g-expressing), vaccinia-specific CD8+ T cells as 
compared to mice inoculated with PBS. Moreover, the magnitude of response was similar 
for vK1L or vDK1L infection (Fig. 9A, 9B). Slightly different results were observed 
when examining lymph nodes of infected animals. While both viruses induced an 
increase in the percentage of VACV-specific CD8+ T cell populations, only vDK1L-
infected mice showed a statistically significant increase as compared to PBS.  When the 
absolute number of VACV-specific CD8+ T cells in lymph nodes were evaluated (Fig. 
9D), there was a greater number of CD8+ T cells in vDK1L-infected versus vK1L-
infected mice.  However, both values were higher than PBS-inoculated mice. Thus, CD8+ 
T cell responses were similar despite the decrease in initial innate immune responses to 
vDK1L infection. 
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vΔK1L protects against a lethal challenge of vaccinia virus 
Since vDK1L infection raised VACV-specific CD8+ T cell responses equal to or 
greater than vK1L infection, we predicted that vDK1L would be an effective vaccine 
against a lethal vaccinia virus challenge. To test this hypothesis, we used a previously 
described vaccination model in which mice were inoculated ID with PBS, or 104 PFU 
vK1L or vDK1L [32]. At day 30 pi, mice were challenged IN with a lethal dose (5 x 106 
PFU) of vK1L. We choose this dose because others have reported that doses of 105 or 
higher are sufficient to be lethal in the IN model of infection [32, 74]. In addition, Jacobs 
et al. reported that ID vaccination protected mice when mice were challenged with 5 x 
106 PFU of wild-type vaccinia virus [32]. Weight was recorded daily as a proxy for 
protection against the challenge (Figure 9E). All PBS-vaccinated mice rapidly lost weight 
and all mice from this group were euthanized by day 6 pi. vK1L-vaccinated mice were 
protected from the challenge. Mice did not lose as much weight as PBS-inoculated mice, 
and mice nearly recovered their original weight by day 14 pi. vDK1L vaccination also 
protected mice against a lethal challenge. Interestingly, vDK1L-vaccinated mice showed 
slightly less weight loss than vK1L-vaccinated mice, although these differences were not 
statistically significant. Thus, vDK1L is a less pathogenic virus that still provides 
protection against a lethal virus challenge. 
 
3.4 Discussion 
We report here that vDK1L is less pathogenic in two models of infection. We 
went on to further examine the ID model of infection because results showed that reduced 
pathogenicity was not due to a decrease in virus replication. Instead, reduced 
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pathogenicity correlated with decreased innate immune cell infiltration and decreased 
inflammatory gene expression in ears. It is well-known that the anti-viral immune 
response can inadvertently damage the host to such a degree that it causes disease [64]. 
Thus, we propose that there are two underlying mechanisms responsible for smaller 
vDK1L-induced lesions.  First, the diminished amount of chemokine expression in 
vDK1L-infected ears, which is already observed at day 3 pi, probably results in a 
decrease in infiltrating immune cells, cells which can express damaging cytokines. The 
second reason is that there are lower amounts of pro-inflammatory cytokine gene 
expression at days 3 and 5 pi in ears. Since some of these cytokines are known to have 
immunopathogenic properties, this decreased expression in vDK1L ears may result in 
smaller lesions. Despite these decreased innate immune responses, ID inoculation with 
vDK1L still stimulates VACV-specific T cell responses and provides protection against a 
lethal VACV challenge equivalent to its parental virus. This is the first mutant vaccinia 
virus describing this type of profile. 
To the best of our knowledge, our studies are the first to address the effects of 
K1L itself on viral pathogenesis. These data illustrate two important concepts to both the 
poxvirus and vaccinology fields.  First, the antagonistic functions of immune evasion 
molecules discovered during cell culture-based studies may not necessarily replicate in 
vivo. For example, K1 is well-known as an antagonist of NF-kB [10, 57]. We reported 
that vDK1L infection up-regulated one NF-kB controlled host gene (Tnf) in comparison 
to wild-type VACV in cell lines [57].  Thus, our original expectation was that vDK1L 
infection would increase NF-kB-controlled host gene transcripts above or earlier than 
vK1L-infected ear pinnae. However, we observed the opposite result: nearly all host gene 
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transcripts were decreased in vDK1L- as compared to vK1L-infected ears at all times 
examined (Table 1). This implies that results obtained from cell culture models of 
infection may not mirror results obtained from in vivo models of infection. One other 
report supports this concept: van Buuren et al. reported that transcription of the NF-kB 
controlled Tnf, Il1b and Il6 genes were not altered in organs during intranasal infection 
with an ectromelia virus devoid of the EMV005 NF-kB antagonist [73]. Data here and 
from van Buuren et al. demonstrate our lack of understanding of how these poxviral NF-
kB inhibitors may truly impact viral pathogenesis.  
The second important concept is that an inflammatory immune response triggered 
by wild-type VACV (vK1L) may be in excess of what is required to mount a protective 
immune response. Several recent publications suggest that limited inflammation is 
beneficial for CD8+ T cell activation, which requires signals from antigen, costimulation 
and inflammatory cytokines [26]. Others have suggested that the positive effect of 
inflammatory signals on T cell activation might compromise the quantity and quality of 
memory T cells [3]. Recently it was reported that sensing of a robust inflammatory 
response affects the transition of effector CD8+ T cells to memory T cells [65]. In 
addition, chronic inflammation can disrupt epithelial integrity, which can affect T cell 
migration or access to pathogens [65]. Thus, perhaps a VACV lacking K1L is one 
component for an improved vaccine vector. 
One must keep in mind that K1 is a multi-functional protein, antagonizing not 
only NF-kB [10, 57] but also PKR [76, 77], IRF1 [42] and type I IFN [44]  signal 
transduction pathways. Unfortunately, the K1 regions necessary for each function are not 
yet known. Until such mapping is performed, the specific K1 function that contributes to 
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VACV pathogenesis remains to be determined.  Thus, we cannot rule out that this 
decrease in inflammatory gene expression during vDK1L infection may be due to other 
K1 functions.  
VACV virus encodes for at least 10 inhibitors of NF-kB including K1, A46, A49, 
A52, B14, C4, E3, K7, M2 and N1 [7, 12, 18, 20, 23, 40, 47, 55, 57]. Interestingly, the 
deletion of a single NF-kB antagonist results in an attenuated infection [4, 5, 9, 20, 27, 
40, 62]. It appears that K1L is unique amongst other NF-kB antagonists studied to date in 
vivo. For example, viruses lacking B14R (DB14R) or N1L (DN1L) are each less 
pathogenic in the ID model of infection [4, 11]. However, DB14R and DN1L each 
replicate to a lesser extent than wild-type VACV [4, 11] while vDK1L replicates equally 
as well as VACV in the ear pinnae (Figure 5). Interestingly, DB14R infection increases 
macrophage infiltrates in the ear, and this is suggested to be due to an increase in 
expression of chemokines and cytokines [11]. However, vDK1L infection is associated 
with a decrease in immune cell infiltration. These data higlight that these poxviral NF-kB 
inhibitors are non-redundant in vivo, and argue strongly in favor of a sophisticated multi-
step system used by VACV to master distinct cellular environments as it infects and is 
exposed to myriad organ-specific associated immune responses. Inflammatory gene 
expression profiles similar to the one performed here have identified host responses to 
infection with wild-type VACV [24, 30]. To the best of our knowledge this is the first 
study to report a detailed analysis comparing the inflammatory gene response to virus 
infection in wild-type VACV (vK1L) versus a VACV devoid of an immune evasion 
gene. We propose that the continued use of RT-qPCR or RNAseq to compare the 
immune gene expression profile of ears when using mutant VACV that lack different NF-
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kB antagonists is one approach that may identify how each VACV immune antagonist 
uniquely alters the host response to infection in vivo. 
In agreement with our data, Liu et al reported that deletion of the K1L gene 
attenuates VACV strain TianTan, and that T cell responses remain unaffected by removal 
of K1L. Liu et al also observed that humoral responses were decreased when K1L was 
absent [38]. Humoral responses for vDK1L were not measured here. It is difficult to 
accurately predict if vDK1L would give results similar to vTTDK1L because the parental 
vector (vTT) lacks several genes other than K1L [38, 70]. Nevertheless, we chose to 
examine only CD8+ T cell responses because others have reported that CD8+ T cells 
provide protection against VACV intranasal infection even in the absence of CD4+ T 
cells and B cells [24].  
Investigation of VACV immune evasion molecules has identified important 
strategies viruses use to modulate the immune response. In turn, this information provides 
a greater understanding of how the host detects, responds to, and eliminates virus 
infection [60]. VACV continues to be used as a vaccine vector and as an oncolytic 
therapy. Thus, information about virus-host interactions is also valuable for researchers 
who optimize current poxvirus-based vaccine vectors.  A continuing challenge for 
researchers is to develop a VACV-based construct that is simultaneously efficacious and 
safe. VACV, while highly immunogenic, induces unacceptably high rates of morbidity 
and mortality. Thus, multiple research labs now are modifying VACV to develop vectors 
that retain immunogenicity and have improved safety profiles [46]. One strategy used by 
researchers is to alter the expression of the immune evasion genes of a VACV-based 
vector [54] in an effort to retain VACV immunogenicity and improve safety. We show 
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here that vDK1L infection in mouse ear pinnae has a decreased pathogenicity but no loss 
in its ability to activate an acquired immune response or protect against a lethal VACV 
challenge. Thus, vDK1L may be a useful tool to further understand the relationship 
between viral modulation of innate immunity and development of immune memory, 
information that has practical applications for vaccine design and optimization.  
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3.5 Figures and Table  
 
Figure 3.1 K1L is not essential for virus replication in vitro. Mouse embryonic 
fibroblasts (MEF) were infected with vK1L, vDK1L, vK1Lrev or vDK1LDC7L at 0.01 or 
10 PFU/cell in duplicate. After absorption, cellular monolayers were washed thrice to 
remove unbound viruses.  (A and C) Cells and (B and D) cell-free supernatants were 
collected separately at the indicated time points. (A and C) Intracellular or (B and D) 
extracellular virus titers were quantified by plaque assays using Vero cellular 
monolayers.  Data are expressed as the mean titer per sample +/- SEM. Dashed lines 
represents limit of detection. 
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Figure 3.2 A virus lacking K1L is less pathogenic when introduced by intranasal 
inoculation. Female BALB/c mice (n = 5 per group) were inoculated intranasally with 
(A-C)104 or (B-F) 105 PFU of vK1L, vDK1L or vK1Lrev or PBS and monitored for 14 
days. (A and D) Mice were weighed daily and data were expressed as the percentage of 
weight loss from day 0. Mice were euthanized if more than 25% of their original body 
weight was lost. (B and E) A survival plot was generated based on data from (A and D). 
(C and F) Clinical signs of illness were monitored daily for 14 days and scored. Statistical 
significance was determined by two-way ANOVA.  Asterisks indicate the days in which 
the weight loss or signs of illness induced by vDK1L were statistically different from 
vK1L (P < 0.05). 
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Figure 3.3 vDK1L virus replication is lower than K1L-containing viruses in organs 
from intranasally-infected mice. Female BALB/c mice (n = 5 per group) were infected 
intranasally with 104 PFU of vK1L, vDK1L or vK1Lrev. At the indicated times post-
infection (A) lungs, (B) brains or (C) spleens were collected, and virus titers were 
determined by plaque assay on Vero cellular monolayers.  Titers are expressed as PFUs 
per gram of tissue. Each symbol represents the virus titer from an individual animal, and 
the mean titer is indicated by a line. Statistical significance was determined by Kruskal-
Wallis test. Asterisks indicate data points in which titers from vDK1L-infected mice were 
statistically different from vK1L (P < 0.05). Dashed lines represent the limits of 
detection. 
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Figure 3.4 DK1L is less pathogenic during intradermal infection.  C57BL/6 mice (n = 
5 per group) were infected intradermally with 104 PFU of vK1L, vDK1L or vK1Lrev in 
the left ear pinna, and sizes of resulting lesions were measured daily for 21 days. Data are 
expressed as the mean of lesion sizes ± SEM. Statistical significance was determined by 
two-way ANOVA. Asterisks indicate the days in which the lesion size caused by vDK1L 
was statistically different from vK1L (P < 0.05). 
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Figure 3.5 Virus replication in ear pinnae of intradermally inoculated mice. 
C57BL/6 mice (n = 5 per group) were infected with 104 PFU of vK1L, vDK1L or 
vK1Lrev as indicated. At the indicated days pi, ears were collected, homogenized and 
lysed, and viral titers of lysates were determined by plaque assay.  Data are expressed as 
the mean titer of virus (PFU) per gram of tissue. 
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Figure 3.6 Ultrasound imaging and quantitation of edema longitudinally in 
intradermally-inoculated ears.  C57BL/6 mice (day 3, n = 13 mice per experimental 
group; day 4, n = 10 mice per experimental group; day 5, n = 7 mice per experimental 
group) were either uninfected (UN) or inoculated ID with PBS or 104 PFU vK1L or 
vDK1L in the left ear pinna. (A) Mice were anesthetized and B-mode images (B-mode) 
were collected. The region circled in pink is the field of interest, which contains ear 
tissue.  The field of interest was used for quantitative ultrasonic data (BSC) assessment. 
The BSC color-coding represents the quantitative magnitude of the gray-scale B-mode 
echo data. The color-coded scale on the right is in logarithmic units, with red representing 
the highest magnitude of the BSC, and dark blue representing the lowest magnitude of 
the BSC. (B) BSC data are quantitatively depicted as a function of time. The BSC values 
are expressed as the mean +/-SEM. Statistically significant differences between mice 
inoculated with PBS vs. vK1L was determined by one-way ANOVA and is indicated by 
one asterisk (P < 0.05).  (C) The thickness of the ear was selected from the spatially 
calibrated BSC image (Fig. 6A) for which the pixel dimension was known (68 µm x 68 
µm = 1 mm x 1 mm). The number of pixels was estimated in the region of the BSC 
image that depicted the thickest measure of the color-coded image. Statistically 
significant differences between inoculated mice were determined by one-way ANOVA 
and is indicated by an asterisk (P < 0.05). 
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Figure 3.7 Histological analysis of infected ear pinnae.  C57BL/6 mice (n = 3 per 
group) were inoculated with PBS or 104 PFU vK1L or vDK1L. At the days indicated 
post-infection, ears were collected, fixed in 10% neutral buffered formalin, processed, 
and stained with hematoxylin and eosin for examination with light microscopy 
(100X).  Representative images of the lesions observed in each group are shown. The 
bars show the scale of size.  
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Figure 3.8 vDK1L infection causes a reduced infiltration of immune cells into ear 
pinnae. C57BL/6 mice were inoculated in the left ear with PBS (n= 10) or 104 PFU 
vK1Lrev (n = 7) or vDK1L (n = 7). At 5 d pi, ears were collected and processed. Single 
cell suspensions were prepared from each ear. Data are expressed as the mean number of 
cells per ear ± SEM.(A) Mean number of live cells per ear as determined by trypan blue 
staining. (B-E) Flow cytometry analyses show the mean number of (B) CD45+ cells (C) 
CD45+CD11c+, (D) CD45+CD11b+CD11c-LyC6+Ly6G+ and (E) CD45+CD11b+CD11c-
LyC6+Ly6G- per ear. Statistical significance was determined by (A-D) Kruskal-Wallis or 
(E) one-way ANOVA. An asterisk indicates conditions where there was a statistically 
significant difference between vK1Lrev and vDK1L (P < 0.05).  
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Figure 3.9 vDK1L infection raises VACV-specific CD8+ T cell responses and 
protects against a lethal VACV virus challenge. C57BL/6 mice (n=5 mice per group) 
were inoculated ID with PBS or 104 PFU vK1L or vDK1L. (A-D) At 10 d pi, mice were 
euthanized, and (A, B) spleens or (C, D) lymph nodes were harvested. Single cell 
suspensions were prepared from each sample, and incubated with VACV B8R20-27 
peptide and Brefeldin A. Cells were stained for extracellular CD8 and intracellular IFNg 
and activated VACV-specific CD8+ T cells were quantified by using flow cytometry. 
Data are expressed as the mean ± SEM. (A and C) The percentage of IFNg+CD8+ T cells 
out of the total number of CD8+ T cells. (B and D) The total number of IFNg+CD8+ T 
cells per organ. Statistical significance was determined by one-way ANOVA. Asterisks 
indicate conditions where there was a statistically significant increase between vK1L or 
vDK1L (P < 0.05). ns = not statistically significant. (E) At 30 d pi, mice were inoculated 
IN with 5 x 106 PFU vK1L. Individual animals were weighed daily for the next 7 days. 
Weight loss is expressed as the percentage +/- SEM of the mean weight of the same 
group of animals on day 0. Mice were euthanized if more than 25% of their original body 
weight was lost. 
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Table 3.1 Gene expression during ID virus infection as detected by RT-qPCR. 
 
Data represents the average fold expression level of each gene (2-DDCt) as compared to 
that in PBS-inoculated ears that were harvested at the same day pi (n = 4 ears per group). 
Underlined values indicate a statistically significant difference as compared to PBS-
inoculated mice (P < 0.05). Bolded values indicate statistically significant difference 
between mice inoculated with vK1L versus vΔK1L (P < 0.05). 
 
 
 
 
 
 
 
 
!
! ! day!1!pi! ! day!3!!pi! ! day!5!!pi!
!  vK1L! v∆K1L! vK1Lrev! ! vK1L! v∆K1L! vK1Lrev! ! vK1L! v∆K1L! vK1Lrev!
Chemokines! !! !! !! !! !! !! !! !! !! !! !!
!!Ccl4! ! 0.47! 0.33! 0.54! ! 1.90! 0.62! 1.98! ! 55.97! 4.51! 49.82!
!!Cxcl2! ! 0.48! 0.30! 0.53! ! 1.44! 0.60! 1.15! ! 10.41! 1.99! 8.83!
!!Cxcl5! ! 0.17! 0.14! 0.18! ! 2.71! 0.44! 8.92! ! 29.76! 5.62! 39.96!
!!Ccl2! ! 0.64! 0.80! 0.66! ! 4.28! 2.00! 8.06! ! 12.91! 6.30! 16.27!
!!Ccl5! ! 0.73! 0.69! 0.75! ! 0.54! 0.49! 0.89! ! 7.41! 1.84! 6.84!
!!Cxcl9! ! 1.94! 0.87! 1.07! ! 3.41! 0.95! 8.22! ! 307.96! 87.92! 360.41!
!!Cxcl10! ! 0.91! 0.52! 0.64! ! 9.03! 1.02! 22.95! ! 302.86! 193.49! 419.48!
!!Cxcl1! ! 2.68! 1.52! 2.16! ! 18.23! 10.46! 26.78! ! 13.95! 16.10! 20.90!
Cytokines! !! !! !! !! !! !! !! !! !! !! !! !!
!!Il1b! ! 0.35! 0.24! 0.45! ! 1.57! 0.45! 1.09! ! 12.47! 2.67! 11.38!
!!Il6! ! 0.46! 0.25! 0.44! ! 7.11! 1.73! 19.65! ! 49.03! 13.44! 63.77!
!!Il10! ! 0.54! 0.42! 0.59! ! 2.28! 0.94! 4.12! ! 9.76! 2.93! 12.76!
!!Il7! ! 1.19! 0.96! 0.98! ! 0.70! 0.99! 0.52! ! 0.59! 0.73! 0.61!
!Tnf! ! 1.04! 0.89! 0.91! ! 1.16! 0.94! 0.97! ! 0.86! 0.97! 0.78!
IFNs! !! !! !! !! !! !! !! !! !! !! !! !!
!!Ifng! ! 1.45! 0.71! 1.01! ! 3.40! 1.02! 7.81! ! 247.88! 32.21! 306.88!
!!Ifna4! ! 1.41! 1.40! 1.29! ! 0.60! 0.85! 0.85! ! 0.19! 0.51! 0.22!
!!Ifnb! ! 1.67! 1.41! 1.42! ! 1.23! 1.02! 2.24! ! 0.91! 1.20! 1.17!
ISGs! !! !! !! !! !! !! !! !! !! !! !! !!
!!Isg15! ! 0.83! 0.55! 0.87! ! 3.39! 0.94! 9.27! ! 104.70! 36.81! 115.28!
!!Rnasel! ! 1.07! 0.91! 0.91! ! 0.95! 0.92! 1.23! ! 3.38! 1.52! 3.82!
!!Mx1! ! 0.50! 0.51! 0.53! ! 3.55! 0.99! 9.65! ! 116.42! 68.74! 174.37!
!!Eif2ak2! ! 1.12! 0.95! 1.10! ! 1.29! 1.07! 1.56! ! 2.64! 1.91! 3.02!
Keratinocytes!stress!response! !! !! !! !! !! !! !! !! !!
!!Krt6a! ! 0.40! 0.34! 0.45! ! 1.61! 0.54! 2.12! ! 32.94! 13.01! 37.82!
!!Krt16! ! 0.52! 0.47! 0.52! ! 2.21! 0.87! 2.84! ! 15.39! 6.54! 18.60!
NFFκB!pathway!! !! !! !! !! !! !! !! !! !! !!
!!Nfkb2! ! 1.17! 1.04! 1.02! ! 1.08! 1.12! 0.93! ! 0.52! 0.93! 0.57!
!!Nfkbia! ! 1.14! 0.88! 1.05! ! 0.87! 1.02! 0.71! ! 0.69! 0.83! 0.72!
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Chapter 4: The K1 protein is structurally similar to the NF-kB cellular inhibitor, 
IkBa, and likewise co-immunoprecipitates with NF-kB 
 
4.1 Introduction  
The K1 protein was discovered over 30 years ago [5, 7]. Originally, based on 
structure prediction software SMART, it was thought that K1 consisted of six ankyrin 
repeat domains (ARDs) [17], motifs known for protein-protein interactions [15]. 
However, the elucidation of K1’s crystal structure revealed that it consists of nine ARDs 
[16]. In addition, the crystal structure confirmed that K1 does not contain an F-box 
domain. This is a unique feature of K1 because most other poxviral ARD-containing 
proteins that are known to inhibit NF-kB activation contain this F-box motif.  This 
implies that the K1 mechanism to inhibit NF-kB activation is likely different than the 
mechanism used by other poxvirus ARD-containing proteins, which is confirmed in 
chapter 2. 
ARDs are abundant in cellular proteins but are not common in bacterial or viral 
proteins [1]. Indeed, only three known virus families (Poxviridae, Asfaviridae and 
Polydnaviridae) have genes that encode ARDs. Poxviruses encode multiple viral ARD-
containing proteins (vankyrins) [25, 26], and the functions of some of these proteins are 
known to be involved in functions as diverse as viral replication and virulence. However, 
many of the poxviral vankyrins still have unknown functions [12].  
The cellular IkB proteins are a family of proteins that bind to and inhibit NF-kB 
activation [13].  IkB proteins possess ARDs, which mediate NF-kB-IkB interactions 
[14]. A strategy used by poxviruses and other viruses to inhibit NF-kB activation is to 
encode vankyrins. Each of them employs unique mechanisms to inhibit NF-kB 
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activation, which provides insights as to how K1 might inhibit NF-kB.  For example, the 
myxoma virus encodes the M150R gene, whose product consists of nine ARDs [3].  
M150 localizes to the nucleus by using one of its ARDs as a nuclear localization signal, 
similar to the mechanism employed by IkBa [3]. M150 does not inhibit IkBa 
degradation or NF-kB nuclear translocation.  Instead, it co-localizes with the p65 subunit 
in the nucleus [3].  The mechanism employed by M150 to inhibit NF-kB activation is not 
yet completely understood.  However, it has been suggested that M150 could interact 
with the NF-kB subunit RelA and trap NF-kB after entry to the nucleus.  Work in this 
thesis (chapter 2) demonstrated that K1 also localizes to the nucleus. One hypothesis is 
that similar to the proposed mechanism for M150, K1 traps NF-kB after nuclear 
translocation and prevents it from interacting with co-activator CBP. 
Another example of an IkBa viral homolog is the ARD-containing A238 protein, 
encoded by the African swine fever virus (ASFV) [23] . A238 allows IkBa degradation, 
but binds to free RelA to form a biologically inactivate A238-NF-kB heterodimer in the 
cytoplasm [23]. Moreover, A238 also inhibits post-translational modifications of NF-kB 
by inhibiting p300 transactivation, thereby diminishing p300-mediated acetylation of 
RelA [8]. Similarly, we have found that K1 prevents RelA acetylation (chapter 2).  
Additionally, cowpox virus encodes the CP77 protein, which blocks NF-kB 
nuclear translocation and subsequent activation by binding to the p65 subunit through its 
N-terminal six-ARD region.  Similar to the ASFV A238 protein above, CP77 does not 
block IkBa degradation [4]. The VARV G1R protein family, which includes ECTV 002, 
MPXV 003, CPXV 006, interacts with NF-kB1/p105 and inhibits NF-kB activation [18]. 
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 The function of K1’s ARDs remains a subject of investigation in our lab. 
Determining the contribution of K1’s ARDs to NF-kB inhibition was the original scope 
of my thesis project. Although the effect of removing one or two ARDs still remains 
unstudied, this chapter describes the tools and advances made to determine the biological 
relevance of K1’s ARDs in NF-kB inhibition.   
 
4.2 Materials and Methods  
Cells, plasmids and viruses 
Human embryonic kidney 293T (293T) cells and Vero cells were obtained from 
the American Type Culture Collection (ATCC). Cells were cultured in Eagle’s minimal 
essential media supplemented with 10% FBS, 2mM L-glutamine, 100 U/mL penicillin 
and 100 µg/mL streptomycin. Virus medium (MEM supplemented with 2.5% FBS) was 
used for virus absorption phases and virus infections.  
Plasmid pHA-K1 consists of a hemagglutinin epitope-tagged K1L gene inserted 
into the pCI expression vector [27]. Plasmids were transfected into cells using the Fugene 
6 (Promega) or TransIt (Mirus) reagents following manufacturer’s instructions.  
Vaccinia virus western reserve strain (vK1L) and modified vaccinia Ankara 
(MVA) were obtained from Dr. Bernard Moss (Laboratory of Viral Diseases, National 
Institutes of Health). vΔK1L is a WR virus in which the K1L gene was replaced with the 
Escherichia coli gpt gene by homologous recombination. The MVA/K1L virus contains 
the vaccinia virus western reserve strain K1L gene stably inserted into the del III region 
of MVA, and was a gift from Gerd Sutter (Institute for Molecular Virology, Munich, 
Germany).  
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Three-dimensional structure alignment  
To compare the protein structures of IkBa and K1, the Flexible structure 
AlignmenT by Chaining Aligned fragmenT pairs allowing twists (FATCAT) algorithm 
was used [28]. The three-dimensional structures of both Ikba and K1 were obtained from 
the protein data bank website (IkBa; PDB ID: 1 IKN and K1; PDB ID: 3KEA) [14, 16].   
 
Immunoprecipitations  
To detect RelA-CBP interactions, subconfluent cellular monolayers of 293T cells 
in 6-well plates were transfected with 2000 ng of pHA-K1 or pCI using Fugene 6. At 24 
h post-transfection, dislodged cells were centrifuged (14,000 rpm for 1 min) and the 
cellular pellet was resuspended in RIPA buffer (150 mM NaCl, 1% sodium deoxycholate, 
1% NP-40, 0.1% SDS, 0.01 M Tris-HCl pH 7.4) for 30 min on ice.  Lysates were 
centrifuged (14,000 rpm for 10 min). A portion of each clarified lysate was removed to a 
new tube and used to probe protein expression in cellular lysates. Protein concentration of 
lysates was determined by bicinchoninic (BCA) assay (Pierce). The remaining clarified 
lysates were placed in a new tube and incubated with 1 µl of anti-RelA antibodies (Santa 
Cruz; sc-8008 X) for 1 h. Then protein G-Sepharose beads (Life Technologies) were 
added to the mixture and incubated overnight at 4° C.  Next, beads were washed in large 
volumes of RIPA Buffer.  Beads were mixed with 2x sample buffer containing 2-
mercaptoethanol and boiled for 5 min. A portion of each immunoprecipitation reaction 
was separated by SDS-PAGE.  Proteins were transferred electrophoretically to PVDF 
membranes and membranes were blocked in 5% (w/v) milk in Tris-Buffered Saline and 
Tween 20 (TBST; 150 mM NaCl, 50 mM Tris base, 0.05% Tween 20) for at least 30 min 
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at room temperature were then incubated with anti-HA antibody (1:1,000; Sigma) and 
then HRP-conjugated goat anti-mouse IgG (1:5,000; Thermo Scientific). Antibody 
reactions on membranes were detected by using chemiluminescence reagents (Amersham 
and Thermo Scientific) and autoradiography.  
 
Luciferase assays 
A dual-reporter luciferase assay was performed to quantify NF-kB activation in 
infected cells using previously published protocols [21, 22, 24]. Subconfluent 293T 
cellular monolayers were transfected with 112.5 ng pNF-kBluc and 12.5 ng pRL-null 
(Promega).  24 h later, cells were either mock-infected or infected with vK1L, vΔK1L, 
MVA or MVA/K1L at a multiplicity of infection (MOI) of 10 PFU/cell.  At eight hours 
post-infection, cells were lysed in 1X Passive Lysis Buffer (PLB; Promega) and lysates 
were analyzed as described previously. 
 
Plasmids construction 
 (This work was performed by Arielle B Guzman, an undergraduate student working 
under my supervision) 
A panel of recombinant viruses expressing either wild-type K1 or K1 mutants 
each lacking one or two ARDs (D1-D7) was obtained from Dr. Yan Xiang (University of 
Texas Health Science Center) [17]. Since these deletion mutants were generated before 
K1’s crystal structured was elucidated, each deletion number does not correspond to the 
ARD deleted (e.g. D1 does not correspond to a deletion of the ARD 1, but instead ARD 2 
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is deleted). A schematic of the corresponding ARD deleted in each mutant is shown in 
Figure 4.3.  
To clone each K1 deletion mutant into the pCI mammalian vector, viral genomes 
were collected. Briefly, confluent monolayers of Vero cells in 6-well plates were infected 
at an MOI of 5 PFU/cell. At 18 h post-infection, cellular and viral genomes were 
collected using the DNeasy Blood and Tissue Kit (Qiagen) following manufacturer’s 
instructions.  
To insert an HA-tag on the N-terminus, and remove the V5-tag on the C-terminus 
of each mutant, the wild-type or each mutated K1L gene was PCR amplified from 
collected viral genomes using primers (5’GGTTAGAATTCGCCACCATGGATTATCC 
ATATGATGTTCCAGATTATGCTGATCT GTCACGAATTAATACTTGG-3’) and 
(5’GTACAGCGGCCGCTCAG TTTTTC TTTACACA ATTGACGTA-3’) and Phusion 
High-Fidelity DNA Polymerase (New England BioLabs). PCR amplicons were purified 
using PCR Purification Kit (Qiagen) and analyzed by electrophoresis. PCR products and 
pCI plasmid were cut with EcoRI-HF and NotI-HF restriction enzymes (New England 
BioLabs) at 37° C for 15 min. Digested products were analyzed by electrophoresis and 
purified using the QIAquick Gel Extraction Kit (Qiagen). Purified cut PCR product and 
plasmid were ligated at a 3:1 or 6:1 ratio using T4 DNA ligase (New England BioLabs) at 
room temperature for 20 min. Insertion of K1L gene into pCI was confirmed by double 
digestion with EcoRI-HF and NotI-HF. Sequence integrity of the K1L gene was 
confirmed by sequencing.  
To analyze the expression of each K1 mutant, subconfluent cellular monolayers of 
293T cells in 6-well plates were transfected with 1500 ng of pHA-K1WT, pHA-D1, 
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pHA-D2, pHA-D3, pHA-D4, pHA-D5, pHA-D6, pHA-D7 or pCI using TransIt. At 24 h 
post-transfection, dislodged cells were centrifuged (14,000 rpm for 1 min) and the 
cellular pellet was resuspended in CE buffer with HALT for 15 min on ice.  Lysates were 
centrifuged (14,000 rpm for 1 min) and clarified supernatants were removed to fresh 
tubes. Protein concentration of lysates was determined by BCA assay. Thirty µg of 
cytoplasmically-extracted protein from each sample was evaluated for K1 protein levels 
by using immunoblotting, in which immunoblots were incubated with mouse anti-HA 
antibody. Blots were re-probed with rabbit monoclonal anti-β-actin antibody (1:5,000; 
Sigma) and then HRP-conjugated goat anti-rabbit IgG (1:10,000; CalBiotech). 
 
4.3 Results  
K1 and IkBa are structurally similar 
 IkBa, the cellular inhibitor of RelA-p50 heterodimers, contains 6 ARDs [14]. 
Interestingly, the K1 protein also contains ARDs [16]. The amino acid sequences of both 
K1 and IkBα (specifically the region involved in NF-kB binding) show no significant 
similarity (data not shown). However, the 3D structures of K1 and IkBα proteins were 
significantly similar (P value of 2.28e-09) as determined by Flexible structure Alignment 
by Chaining aligned fragment pairs allowing twists (FATCAT), which defines significant 
similarity by a P value < 0.05 [28].  Both the 3D structure alignment and the aligned 
amino acid sequences based on the structural alignment are shown in Figure 4.1.  In 
addition, the IkBα residues involved in NF-kB interactions and the corresponding 
aligned amino acid of the K1 protein are shown in Table 4.1.  
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The K1 protein co-immunoprecipitates with NF-kB 
IkBa inhibits NF-kB activation by binding to NF-kB [11]. I hypothesized that, 
due to their structural similarity, K1 would also be able to bind to NF-kB. To test this 
hypothesis, co-immunoprecipitation assays were performed in which endogenous RelA 
(NF-kB subunit) was pulled down and bound K1 was detected by immunoblotting. 
Figure 4.2 shows that K1 and RelA co-immunoprecipitated in both unstimulated or TNF-
stimulated conditions. However, this co-immunoprecipitation assay needs to be 
optimized since it was very challenging to repeatedly detect those interactions. This 
raises the possibility that K1 may bind to another cellular factor such as CBP instead of 
NF-kB or that a viral protein stabilizes these interactions since these co-IPS were 
performed independently of infections.  
 
Expression of K1 ARD mutants 
 The original scope of this thesis was to determine if binding to RelA contributes 
to K1’s NF-kB inhibitory mechanism. If K1-NF-kB interactions are biologically relevant, 
I rationalized that a mutant that has lost its ability to bind to RelA should then lose its 
NF-kB inhibitory function. A panel of recombinant viruses each expressing a V5 epitope-
tagged mutant K1 protein that lacks one or two ARDs was obtained (Fig 4.3) [17]. I 
expected to use this panel of mutant viruses to test the biological relevance of K1-NF-kB 
interactions by testing the ability of each mutant K1 protein to inhibit and bind to NF-kB. 
However, these viruses could not be used for these purposes because I did not observe 
NF-kB activation or IkBa degradation in 293T cells infected with vDK1L (Figure 4.4A 
and 4.4B, respectively).  NF-kB–controlled luciferase activity levels were low in mock-
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infected cells or in vK1L- or vΔK1L-infected cells, indicating that NF-kB remained 
inactive under these conditions (Fig. 4.4B).  Some cells were instead infected with MVA, 
an attenuated strain of vaccinia virus that lacks the K1L gene and other immune evasion 
genes as a positive control [2]. As shown previously, MVA infection stimulated NF-kB 
in this cell line [24] [20]. In contrast, infection with a recombinant MVA/K1L resulted in 
inhibition of NF-kB (Fig 4.4B). Taken together the K1 protein is sufficient, but not 
required to inhibit NF-kB activation in 293T cells.  
 Data from an IkBa degradation assay complemented results from Figure 4.4A: 
IkBa degradation was observed by immunoblotting and the intensity of these IkBa-
containing bands was similar to the band observed in mock-infected cells, inferring that 
virus infection itself, regardless of the presence or absence of K1L, did not stimulate NF-
kB. Similarly, IkBa remained present when infected cells were incubated with TNF, a 
cytokine that is an extrinsic stimulator of NF-kB [10], and this is not surprising given that 
VACV encodes proteins that inhibit NF-kB activation reference. Notably, IkBa was no 
longer detectable in mock-infected cells that were treated with TNF, showing that 293T 
cells had the capacity to respond to NF-kB-inducing stimuli.  Since K1 is not required to 
inhibit NF-kB, I could not use this panel of mutant viruses in the 293T cell line to map 
the K1 region containing NF-kB antagonistic activity.   
One alternative to study the effects of removing one ARD in K1’s inhibitory 
function is to express these mutants in an MVA/K1L background. However, results from 
chapter 2 concluded that viral infections are not suitable to study NF-kB inhibition by K1 
due to the cofounding effects of other viral proteins still present in VACV or MVA. 
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Thus, the best approach to study the role of K1’s ARDs in NF-kB inhibition is to express 
each mutant independently of viral infection. Previous undergraduate students working 
under my mentoring cloned recombinant V5-tagged K1L genes into the pCI mammalian 
expression vector. However, these plasmids exhibited a poor and inconsistent K1 
expression in 293T cells.  Since epitope tags can alter protein expression, we created a 
second set of mutant constructs in which we engineered an HA tag in place of the V5 tag. 
We chose the HA epitope because an HA-tagged K1 protein expressed from pCI showed 
consistent expression throughout multiple experiments in chapter 2 of this thesis. Data 
from Figure 4.5 showed that each HA-tagged K1 mutant protein was expressed in 293T 
cells. We have noticed that these mutant K1 proteins consistently have decreased 
expression as compared to wild-type K1 proteins. Interestingly, this decreased expression 
was also observed during infection [17].   The next goal is to use these proteins in our 
acetylation assays discussed in chapter 2 as a read-out for which K1 region possesses NF-
kB antagonistic function. 
 
4.4 Discussion  
Here I show that the K1 protein ARDs are structurally similar to the ARDs in 
IkBα. In addition, I show that, similar to IkBα, K1 co-immunoprecipitates with NF-kB. 
However, these interactions were difficult to observe consistently, despite multiple 
attempts to repeat or optimize assays to detect RelA-K1 interactions.  
 Despite this lack of reliability, I believe that RelA-K1 interactions might 
contribute to K1’s NF-kB inhibitory mechanism. However, I hypothesize that K1’s 
mechanism is different from the one employed by IkBα. RelA-IkBα interactions mask 
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RelA nuclear localization signal (NLS) and keep NF-kB inactive in the cytoplasm [14]. 
Results from chapter 2 show that NF-kB localized to the nucleus in the presence of K1. 
Thus it is unlikely that K1-RelA interactions mask NF-kB’s NLS. In addition to blocking 
NF-kB nuclear translocation, RelA-IkBα interactions cause a conformational change that 
induces allosteric inhibition of NF-kB-DNA binding [14]. However, work from chapter 2 
does not support a conformational change as a result of RelA-K1 interactions since K1 
allows NF-kB to interact with an oligonucleotide containing NF-kB binding sites.  
RelA is acetylated by CBP/p300, a post-translational modification that is required 
for NF-kB full transcriptional activity [6, 19]. For this acetylation to occur CBP/p300-
RelA interaction must occur. I have shown that neither acetylation or CBP-RelA 
interactions occur in the presence of K1 (chapter 2). Thus our current hypothesis is that 
K1 binds to RelA in the same region that CBP/p300, does preventing CBP-RelA 
interactions.  Interestingly, the ASFV A238 vankyrin also utilizes a CBP/p300-dependent 
mechanism to inhibit NF-kB activation by preventing the recruitment of CBP/p300 to the 
enhanceosomes [9]. This raises the possibility that some vankyrins share a similar 
mechanism to prevent NF-kB activation.   
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4.5 Figures and Table 
 
 
Figure 4.1 The 3D structures of K1 and IκBα are significantly similar. (A) Sequence 
alignment obtained using Flexible structure AlignmenT by Chaining Aligned fragment 
pairs allowing Twists (FATCAT). The two structures are significantly similar with a P-
value of 2.28e-09. Blue residues: structurally equivalent, but not similar; Pink residues: 
structurally equivalent, and similar; Green residues: structurally equivalent and identical 
residues.  (B) Graphic representation of the alignment. Green: K1; Blue: IκBα. 
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Figure 4.2 The K1 protein immunoprecipitates with NF-κB. 293T cells were 
transfected with pCI or pHA-K1. At 24 h post-transfection, cells were incubated in 
medium lacking (UN) or containing TNF (10 ng/mL). Cells were lysed in RIPA buffer at 
the indicated time. Immunoprecipitation (IP) was performed by incubating lysates with 
anti-RelA antibody for 1 h and then protein G-sepharose beads were added for overnight 
incubation. IPs or 30 µg of lysates were subjected to 12 % SDS- PAGE and transferred to 
PVDF membranes. Blots were incubated with anti-HA antibodies. 
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Figure 4.3 Schematic of K1 mutants. The wild-type K1 protein possess nine ARDs, 
each depicted as a purple box (WT). Each mutant (D1-D7) lacks one or two ARDs. The 
corresponding ARD in each mutant is depicted as a white box.   
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Figure 4.4 The K1 protein is not required to inhibit NF-κB activation in infected 
293T cells. (A) 293T cell monolayers were either mock-infected or infected with WR or 
ΔK1L (MOI = 5). At 3 h pi, cells were incubated in medium lacking (UN) or containing 
TNF (10 ng/mL) for 20 min. Cells were lysed in CE buffer. Equal amounts of 
cytoplasmic extracts (15 µg) were separated by 10% SDS-PAGE and transferred to a 
PVDF membrane. Immunoblots were probed with anti-IκBα antibody and re-probed with 
anti-actin antibodies. (B) Sub-confluent 293T cellular monolayers were transfected with 
112.5 ng pNF-κBluc and 12.5 ng pRL-null. At 24 h post-transfection, cells were mock-
infected or infected with the indicated viruses (MOI = 10). At 8 h pi, cells were lysed, 
and firefly and sea pansy luciferase activities were measured. Experiments were 
performed in triplicate and data show the average luciferase/sea pansy ratio normalized to 
the value obtained from mock-infected cells, for which the value was set to 1. Error bars 
represent standard deviation. 
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Figure 4.5 Expression of K1 ARD mutants. 293T cells were transfected with 1500 ng 
of pCI, pHA-K1 or plasmids encoding for K1 mutants (pHA-D1 to pHA-D7). 24 post 
transfection cells were lysed in CE buffer. Cellular lysates were separated by SDS-PAGE 
and then transferred to PVDF membranes.  Membranes were probed with anti-HA 
antibodies, and then the same blots were re-probed with anti-b-actin antiserum. 
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Table 4.1 Comparison of IkBα residues contacting NF-kB with corresponding K1 
residues. 
Residue 
in IkBα 
Residue 
in K1 Contact with NF-kB Similarity 
Glu 138 Leu p50 DD Structurally equivalent; not similar residues 
Leu 150 Gln RelA NLS Structurally equivalent; not similar residues 
Glu 153 Thr RelA NLS Structurally equivalent; not similar residues 
Gln 154 Leu RelA NLS Structurally equivalent; not similar residues 
Tyr 181 Asp p50 DD Structurally equivalent; not similar residues 
Pro 214 Lys p50 DD Structurally equivalent; not similar residues 
Cys 215 Thr p50 DD Structurally equivalent; not similar residues 
Asn 216 Gly p50 DD Structurally equivalent; not similar residues 
Arg 218 Lys RelA DD Structurally equivalent; similar residues 
Thr 247 - p50 DD - 
Tyr 248 - p50 DD - 
Tyr 251 Leu RelA DD Structurally equivalent; not similar residues 
Leu 256 Ile p50 DD, RelA DD Structurally equivalent; similar residues 
Trp 258 Ile RelA  ATD,  RelA  DD Structurally equivalent; not similar residues 
Arg 260 Asn RelA  DD Structurally equivalent; not similar residues 
Gln 266 Met RelA ATD Structurally equivalent; not similar residues 
Leu 269 Leu RelA ATD structurally equivalent; identical residues 
Gln 271 Asp RelA ATD Structurally equivalent; not similar residues 
Met 279 Pro RelA DD Structurally equivalent; not similar residues 
Leu 280 Asp RelA DD Structurally equivalent; not similar residues 
Glu 282 Glu RelA DD Structurally equivalent; similar residues 
 
DD: Dimerization domain; NLS: nuclear localization signal; ATD: Amino terminal 
domain. 
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Chapter 5: Summary and Future Directions 
 
5.1 Summary 
 This thesis project describes several novel findings about the anti-inflammatory 
effects of the K1 protein. Our lab has previously published that the K1 protein inhibits 
NF-kB activation as an indirect effect of inhibiting the upstream activator PKR. In 
addition, the effects of lacking the K1 protein on VACV pathogenesis were unknown. 
Here, I discovered a novel PKR-independent mechanism by which K1 inhibits NF-kB 
activation. Also, I found that VACV lacking the K1 protein (vDK1L) is attenuated in two 
animal models of infection.    
 The K1 protein is known to inhibit the activation of the dsRNA sensor PKR, and 
it was originally hypothesized that inhibition of IkBa degradation and subsequent NF-kB 
activation was solely an effect of PKR inhibition. However, I have found that K1 not 
only inhibits NF-kB in PKR deficient cells, but also allows NF-kB nuclear translocation 
and DNA binding, events that occur after IkBa degradation in the NF-kB signaling 
pathway. These observations suggested a PKR-independent mechanism. Indeed, in this 
mechanism, K1 prevents NF-kB-CBP interactions and consequently CBP-mediated NF-
kB acetylation. This is the first report of a VACV protein inhibiting NF-kB acetylation, 
one of the most downstream events in NF-kB signaling.    
 Although K1 has been shown to inhibit multiple anti-viral immune responses, 
such as NF-kB, PKR, and IFN in cell culture models of infection, no studies have 
investigated the effects of removing K1 from VACV in viral pathogenesis. I have found 
that vDK1L is attenuated in two animal models of infection, IN and ID, measured by 
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weight loss and lesion size, respectively. In the IN model, I observed that vDK1L 
replicated less than wild-type VACV and had limited spread.  In contrast, in the ID 
model, there was no difference in viral replication between wild-type VACV and vDK1L. 
However, I saw a decrease in inflammatory gene response in vDK1L-infected mice as 
compared to VACV, despite K1’s known NF-kB inhibitory function in cell culture. This 
unexpected result reconfirms that animal models of infection are needed to truly 
understand the contributions of immune evasion proteins to viral pathogenesis. Although 
vDK1L induced a moderate inflammatory gene expression, vDK1L was protective against 
a VACV lethal challenge. This suggests that the robust inflammatory gene expression 
induced by VACV is an excess of what is needed to mount a protective immune response 
and that our field still has a lack of understanding of how VACV is such a successful 
vaccine.  
 
5.2 Future Directions  
K1’s nuclear localization  
 I have found that the K1 protein localizes to the cytoplasm and nucleus when K1 
is expressed either by infection or transfection. It is unclear how K1 localizes to the 
nucleus because it lacks a classical nuclear localization signal (NLS). However, other 
ARD-containing proteins such as IkBa and poxviral protein M150 use one of their ARDs 
as a non-canonical NLS. To investigate this hypothesis, mutants described in Chapter 4 
could be utilized to detect changes in K1’s sub-cellular localization when it lacks one 
ARD. Another possibility is that K1 binds to NF-kB and translocates to the nucleus as 
part of a complex. However, this is unlikely because K1 localizes to the nucleus in 
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unstimulated cells, where most of the NF-kB population is cytoplasmic. K1 may 
passively diffuse to the nucleus because K1 is relatively small (32.5 kDa).   
 
How does K1 inhibit NF-kB-CBP interactions? 
 In chapter 2 I described that K1 prevents NF-kB-CBP interactions to prevent 
RelA acetylation and NF-kB activation. How NF-kB-CBP interactions are disrupted by 
K1 still needs to be investigated. I observed that K1 co-immunoprecipitates with NF-kB. 
Thus, our working hypothesis is that K1 binds to the same region of NF-kB that CBP 
does and prevents CBP from docking. Mutational analysis of K1-NF-kB and CBP-NF-
kB interactions can be used to test this hypothesis. As an additional means to confirm that 
K1-NF-kB interactions are biologically relevant for K1’s NF-kB inhibitory function, the  
ARD mutants described in chapter 4 could be tested for their ability to bind to and inhibit 
NF-kB as compared to wild-type K1. I expect that mutants that no longer bind to NF-kB 
should no longer inhibit NF-kB activation (as measured by RelA acetylation). In 
addition, mutants that no longer bind to NF-kB should not disrupt NF-kB-CBP 
interactions to support the hypothesis that K1 and CBP competitively bind to NF-kB. 
This competitive binding could also be confirmed if the NF-kB region to which K1 binds 
to is determined. For this, NF-kB (RelA) mutants could be obtained to specifically 
determine which region K1 binds to, which should be the same region that CBP binds.  
It should be noted that luciferase assays, which are the standard means to evaluate 
NF-kB activation, need to be optimized. During my tenure as a graduate student, there 
were different luciferase assay conditions in which K1would either inhibit or no longer 
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inhibit NF-kB activation. Multiple attempts were tried to obtain the same NF-kB 
inhibitory results by K1. Unfortunately, these attempts were not successful, which could 
be attributed to changes in the luminometer, transfection reagents and cell line stocks that 
occurred over the years. However, NF-kB inhibition by K1 was reliably detected via NF-
kB acetylation assays, suggesting that these assays may be better than luciferase assays. 
In addition, as mentioned in chapter 4, the K1-NF-kB co-immunoprecipitation assays 
need to be optimized since it was very challenging to detect those interactions.  
 
Why is vDK1L attenuated during an intranasal or intradermal infections? 
 Chapter 3 describes how the deletion of K1L from VACV results in an attenuated 
infection during an IN and ID inoculation. Our hypothesis was that a virus lacking K1L 
would be deficient in NF-kB inhibition and subsequently greater infiltration of immune 
cells will occur, which would lead to a faster viral clearance and decreased pathogenesis. 
However, in the ID model of infection, the opposite result was observed and infection 
with vDK1L resulted in a decrease in NF-kB-controlled gene expression.   
 I recognize that IN and ID infections are very different, one being a systemic 
infection and the other a highly localized infection, respectively. Thus, there are several 
future directions for research with respect to IN infection.  First, whether NF-kB 
inflammatory controlled genes are down or upregulated in lungs of vDK1L-infected mice 
as compared to wild-type VACV should be determined. The approach utilized to 
determine the expression of inflammatory genes during an ID infection was Fluidigm, 
which allowed for the simultaneous quantification of 24 cellular genes. This same 
approach can be used again with lung tissues. During ID infection I have observed a 
	   147	  
decrease in inflammatory gene expression in vDK1L-infected ears as compared to wild-
type VACV-infected ears. However, during IN infection I expect the opposite; an 
increase in the gene expression of cytokines and chemokines in vDK1L-infected lungs, 
which would result in an increase in immune cell infiltration. These immune cells could 
promote rapid viral clearance and explain the decreased replication of vDK1L as 
compared to wild-type VACV, which is not observed during ID infection. The prediction 
of an opposite effect during ID and IN models could be supported by K1 employing 
different antagonistic functions (NF-kB or PKR) in each model.  
 One limitation of our Fluidigm platform is that it has only monitored the 
transcription of 24 host genes. One goal is to use RNAseq from infected tissues to obtain 
a global picture of host responses to virus infection. This information could provide a 
better understanding of how K1L alters the local environment to support viral replication 
and spread.   
 Other NF-kB deletion mutant VACVs, such as DK7R,  have a different 
infiltration pattern of immune cells to the lungs and ears as compared to wild-type VACV 
[2]. It will be beneficial to determine if vDK1L infection leads to more or less infiltration 
of immune cells via flow cytometry, which could help to understand why vDK1L 
infection results in decreased pathogenesis. During ID infection, I hypothesize that there 
will be less infiltration of immune cells during vDK1L as compared to wild-type VACV 
since there is a decreased expression of chemokines during vDK1L infection. However, 
as described above, I expect an increase in immune cells infiltration during IN vDK1L 
infection.   
 
	   148	  
 Does K1 inhibit NF-kB or PKR activation in vivo? 
K1 is a known inhibitor of anti-viral immune responses such as PKR and NF-kB 
in cell culture models of infection. Thus, the decreased in NF-kB-regulated genes during 
vDK1L intradermal infection was unexpected. However, it remains unknown if it is K1’s 
role as an NF-kB or PKR antagonist that is responsible for this phenotype. To answer this 
question, I propose two approaches.  The first is to examine NF-kB and PKR activation 
from infected tissues of mice by either: (i) performing immunoblotting from mice tissues 
to measure acetylation of NF-kB, an event blocked by K1 in cell culture, (ii) in vivo 
luciferase assay imaging or (iii) ex vivo luciferase assays. In addition, immunoblotting 
could also be employed to measure PKR activation during vDK1L infection.  
Second, mutant K1 proteins from chapter 4 that lack either NF-kB or PKR 
inhibitory function (or both) could be used to determine which of these two K1 functions 
is important for VACV pathogenesis. First, the inhibitory phenotype of each mutant for 
PKR and NF-kB activation should be tested in vitro. (In addition, the ability of each 
mutant to inhibit IFN should be determined as this is another K1 function.) Once each 
mutant is characterized in cell culture, the pathogenicity of viruses expressing mutant K1 
proteins that either inhibited only PKR, only NF-kB, or both PKR and NF-kB, could be 
compare using both the IN and ID models of infection. The ultimate goal would be to 
correlate virus virulence with one or more of the K1 antagonistic functions.  
 
Why does VACV encode multiple inhibitors of NF-kB? 
It is still elusive why VACV encodes more than 10 inhibitors of NF-κB. Since 
deletion of any of these inhibitors results in an attenuated virus [1-8], each of them must 
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play a critical role in VACV pathogenesis. I hypothesize that NF-κB inhibition in vivo by 
each inhibitor occurs in a time-dependent and spatially-specific manner. Once the best 
approach to measure NF-κB activation in vivo is determined, a comparison of NF-κB 
activation at different times and tissues during infection with VACV mutants lacking one 
NF-κB inhibitor should be performed. I believe that activation of NF-κB would be 
observed at different times and at different organs during infection with these viruses. 
This will shed light into the non-redundancy of these NF-κB inhibitors.  
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